Note: Descriptions are shown in the official language in which they were submitted.
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
KYBERDRUG AS AUTOVACCINES WITH IMMUNE-REGULATING EFFECTS
FIELD OF THE INVENTION
The present invention relates to a biologically
active material isolated from non-pathogenic bacteria,
pharmaceutical compositions containing same and methods
for treating viral and bacterial infections and maladies
caused by viruses, including retroviruses and bacteria.
BACKGROUND OF THE INVENTION
The gastrointestinal tract of humans and
animals contains a large number of pathogenic bacteria
that are prevented from reaching the systemic circulation
by the presence of an effective mucosal barrier. In
healthy humans and animals, toxins and a small number of
microorganisms continuously break the epithelial lining
of the gut; nevertheless, further migration of the
bacteria is prevented by the action of gut-associated
lymphoid tissues or by certain specific cells like
leukocytes and their subgroups or, if present, impaired
lymphocytes. However, many host responses to traumas,
burns, chemotherapy, inflammatory diseases and secondary
infections have been shown to cause an increase in the
permeability of the intestinal tissue and the bowel to
microorganisms and viruses as well as toxins. Such
changes in intestinal permeability can originate from
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
translocation of bacteria, i.e., the process by which the
endogenous gut flora penetrate the intestinal barrier and
invade sterile tissue. As a result, T-cell immunity is
impaired, and endotoxins are formed and released, causing
damage to the intestinal lumen and more importantly to
the intestinal barrier. This action allows the
intestinal bacteria and endotoxins to invade more deeply
into the host, thereby amplifying the host's response to
the infection and causing a prolonged or life-threatening
course of the disease. The enhancement of intestinal
permeability due to the release of bacterial endotoxins
has deleterious effects not only on T-cell lymphocytes
and enterocytes, but more importantly on the cell-cell
mediators, e.g. cytokines, including growth factors and
interferons. Moreover, the enhancement of intestinal
permeability impairs the immune system of the patient,
creates inflammation in the patient and causes tissue
remodeling.
A type of bacteria endogenous to the gut which
is translocated and causes the deleterious effects
described hereinabove is the enterobacteriaceae. These
are a family of gram negative, facultatively anaerobic
bacteria that are widespread as parasites and pathogens
of animals, including humans and plants. Examples
include the intestinal bacteria E. coli and Proteus
vulgaris. Another bacteria that causes these deleterious
effects is the Salmonella. The enterobacteriaceae are
found in feces, pus, sputum, urine, and skin of mammals
as well as in infected areas in the mammals, especially
those caused by bacteria and viruses, including those of
inflammatory diseases.
-2-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
Bacterial translocation includes the migration
of microbial organisms to various tissues, such as lymph
nodes, spleen, liver, blood and the lungs. The
translation of these bacteria may have deleterious
effects. For example, the presence of endotoxins within
the distal airspace of the lung induces an inflammatory
response that results in the accumulation of neutrophils
and the formation of edema within 24 hours. The response
is attributed to the effect of endotoxin on epithelial
cells, alveolar macrophages, and endothelial cells
inducing the production of cytokines. These cytokines
subsequently induce upregulation of adhesion molecules
and acute migration of neutrophils and, at later times,
mononuclear cells.
It is believed that the deleterious effects are
attributable to an endotoxin produced by the
enterobacteriaceae and injected into the cell. This
endotoxin is or contains lipid A. Gram-negative bacteria
contain lipid A. Lipid A is the major element in the
lipopolysaccharide molecules that coat the surface of all
Gram-negative bacteria. The general structure of the
lipopolysaccharide is as follows:
(oligosaccharide repeating units-core oligosaccharide-
(ketodeoxyoctanate)3-lipid A.
Lipid A.is a diphosphorooligosaccharide which contains a
glucosamine backbone to which generally are linked long
chain fatty acids. More specifically, it consists of a
backbone of (13, 1-6) linked D-glucosamine dissaccharide
which carries phosphate residues in positions 1 and 4' on
the sugar ring. Amidated or esterified long chain fatty
-3-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
acids (generally D-3-hydroxy and/or acyloxy fatty acids)
are present in each of the possible sites in the
glucosamine moieties.
The lipid A moiety is the portion of the
endotoxin which is responsible for the deleterious and
lethal effects. Moreover, the chemical structure of
lipid A is the most constant among the different genera
of gram-negative bacteria.
The Lipopolysaccharides are anchored to the
outer surface of the outer membrane of the
enterobacteriaceae via covalently linked lipid A, and
they are released into the tissue when the
enterobacteriaceae invade the host.
The unwanted toxic effects are associated with
the pathophysiological activities of free lipid A, e.g.
the induction of endotoxic shock, pyrogenicity,
macrophage activation, 13-lymphocyte mitogenicity,
induction of unspecific interferon production, complement
activation and human tumor regression (see e.g., C.
Galanos et al., Int. Rev. Biochem. 14, 280-288, (1977);
C. Galanos et al., Eur.J.Biochem. 31, 230-233, (1972); C.
Galanos, et al. Eur. J.Biochem., 9, 245 - 249, (1969);
Weinberg et al., J.Immunol., 121, 72-80, (1978); E.E.
Ribi et al., J.Natl Cancer Inst., 55, 1253-1257 (1982)).
However, the endotoxins also contain a portion
which has beneficial effects to the animal, i.e., the
oligosaccharide repeating unit (0-chain). It plays a
role in protecting the cell from cell death and
phagocytosis, even though the presence of this 0-
specific antigen is not necessary for the survival of the
bacteria in vitro.
-4-
CA 02436107 2003-04-04
WO 02/28424 PCT/IBO1/02284
The lipopolysaccharides also carry
immunodominant structures (0-factors) against which the
host immune system produces antibodies. Therefore, the 0-
specific chain is responsible for the 0-antigenic
properties of the lipopolysaccharides. The 0-factor has
also been found to promote such beneficial effects as
suppressing tumor growth by stimulating certain specific
cytokines and interferons, inhibiting foreign bacterial
invasion, inhibiting viral adhesion to cells and/or
tissue of the animal, stimulating individual defense
mechanisms against invading bacteria through immune-
modulating mediators and specific humor factors of the
cellular immune response, suppressing cellular stimuli
responsible for inflammation, suppressing bacteria and
virus infiltration, enhancing macrophage activation and
complement (MHC) activation, reducing lymphocyte
mitogenicity and minimizing endotoxic shock and
pyrogenicity. In addition, other attributes possessed by
this biological material include the potential to inhibit
the expression of target molecules in vivo, i.e., ICAM-1
or laminan like adhesion molecules, and to re-regulate
the message to specific cytokines and/or interleukines,
adhesion molecules (ICAM) and viruses by preventing up-
regulation of expression of endothelial cells and
inhibiting colitis (M. Crohn) and caragellnan-induced
neutrophil migration into the subcutaneous or intestinal
epithelial space.
The endotoxin produced by the
enterobacteriaceae has both beneficial and detrimental
effects. The beneficial effects lie in the 0-
polysaccharide portion of the molecule, whereas the
endotoxic properties reside entirely on the lipid A
-5-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
moiety. However, in the intact bacteria,
lipopolysaccharide and lipid A are in a complex with
phospholipid and protein, respectively.
Thus, these bacteria exhibit both beneficial
and adverse effects. These bacteria, particularly the
enterobacteriaceae (e.g., E. Coli), produce compounds
which provide immunostimulating effects, but, at the same
time, also provide the deleterious and lethal side
effects. Thus, the objective was to find a way to
minimize the deleterious effects and to maximize the
beneficial effects.
The detoxification of deleterious compounds and
the use thereof has been described in the art.
U.S. Patent No. 4,436,727 describes the
production of a refined detoxified endotoxin which, when
combined with cell wall skeleton, resulted in a
therapeutically effective composition for the treatment
of cancerous tumors without the deleterious side effects
which are normally associated with endotoxins.
Furthermore, the detoxified endotoxin described therein
is prepared from batch cultures of microorganisms after
methanol-chloroform precipitation with subsequent acidic
hydrolysis in order to obtain a crude lipid A fraction.
The purified detoxified endotoxin was combined with the
cell wall skeleton for imparting immunotherapy.
U.S. Patent No. 4,912,094 discloses the
production of modified lipopolysaccharides, particularly
de-3-0-acylated monophosphoryl lipid A and 3-0-acylated
diphosphorphoryl lipid A under strict controlled alkaline
hydrolysis which removes only the 3-hydroxymyrystic acyl
residue that is esterfied to the reducing end of the
glucosamine at position 3. This material is being used
-6-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
against type I hypersensitivity in warm blooded animals
sensitive to allergens, e.g. pollen allergen, mold
allergen, insect salina allergen, insect part allergen,
drug and food allergen.
U.S. Patent No. 5,762,943 describes methods and
compositions for treating type I immunoglobulin E (IgE)-
dependent hypersensitivity by administration of
monophosophoryl lipid A of 3-deacylated monophosphoryl
lipid A. The biologically active material can be
administered as part of a desensitization regimen or as a
Type I of a prophylactic vaccine to prevent a Type I
hypersensitivity reaction.
U.S. Patent No. 5,888,519 discloses high
encapsulated high-concentration lipid A as an immunogenic
agent. This disclosure aims to provide human antibodies
in the form of hyperimmune polyclonal antiserum, or a
human monoclonal antibody reactive with Gram-negative
bacteria including providing effective passive
prophylaxis against or therapeutic treatment of sepsis.
U.S. Patent No. 5,776,468 discloses a novel
vaccine composition comprising small particles of 3-0-
deacylated monophosphoryl lipid A. In particular, it
describes how to prepare a certain particle size of less
than 120nm, which can applied to induce protective
immunity, even with very low doses of antigen. The
specification provides evidence that these compounds
protect against primary and current infections, and
stimulate advantageously both specific humoral by
neutralizing antibodies, and also effector cell mediated
immune response. Moreover, it is alleged that vaccine
compositions comprising small particles of the 3-0-
deacylated monophosphoryl lipid A molecules, especially
-7-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
those below 120nm, as measured by photon correlation
spectroscopy, are useful in providing protection against
hepatitis infections (Hepatitis A,B,C,D, and E), and
herpes (HSV-1 or HSV-2).
However, none of the aforementioned prior art
describes the isolation of biologically active
microorganisms from individual patients, suffering from
acute or chronic infections of bacterial or viral origin,
wherefrom a specifically active material or analog
thereto can be obtained in a form of a viable non-
replicating bacteria.
The present inventors, through a series of
controlled isolation steps, have isolated a biologically
active material which contains the immunostimulating
effects without the toxic side effects.
More specifically, they found a biological material which
minimizes or completely eliminates the toxic effects of
the endotoxin induced translocation of bacteria in the
gut and simultaneously promotes the beneficial effects of
a lipid A-like material.
The present inventors found that this
biological material is non-toxic and yet maintains the
ability to inhibit the growth of other bacteria. It is
known that bacteria can produce proteinaceous compounds
that are lethal against other bacteria; at the same time
the bacterial cell producing these proteinaceous
compounds (called bacteriocins) are immune to its
antagonist action. Thus, the present inventors found and
isolated a biological material which maintained this
property and yet is non-toxic.
The present inventors found and isolated such
biological material. They found that by utilizing a
-8-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
certain isolated strain of bacteria of enterobacteriaceae,
they were able to isolate a compound and prepare a drug
therefrom which makes use of the immunostimulating effects
attributable to this class of bacteria and simultaneously
substantially eliminate the deleterious lethal side effects
due to endotoxin induced translation of bacteria in the gut
and in the gastrointestinal lumen. Moreover, they found
that this isolated material exhibited the attributes
identified hereinabove.
For example, they found that this isolated
material exhibited immuno-stimulating effects. It is
capable of stimulating the appropriate cytokines and
interferons for suppressing tumor growth and inhibiting
foreign bacterial invasion and adhesion of virus to cells.
In addition, it promotes the stimulation of the defense
mechanisms of the animal when invaded by viruses or
bacteria. The isolated material also suppresses cellular
stimuli responsible for inflammation, and suppresses
bacteria and virus infiltration, enhances macrophage
activation, reduces lymphocytic mitogenicity and minimizes
endotoxic shock and pyrogenicity. In addition, this
isolated material from these strain of bacteria re-
regulates soluble and cell associated molecules involved in
the process relating to the recruitment and retention of
leucocytes at local sites of inflammation.
This material which they ultimately isolated from
patients suffering from acute or chronic diseases is called
Kyberdrug.
-9-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
SUMMARY OF THE PRESENT INVENTION
Thus, the present invention is directed to this
isolated bacterial material (hereinafter known as
"Kyberdrug"), the material isolated from viable non-
replicating bacteria described herein.
The material called Kyberdrug was isolated from
individual patients suffering from acute or chronic
diseases and can be successfully administered to mammals in
a dose dependent manner for successfully treating certain
diseases, e.g. viral and bacterial infections. In 0.9%
sodium chloride solution, they form colloidal crystals. In
addition these colloidal crystals of the Kyberdrug as well
as in aqueous solutions exhibit low polydispersity, having
a narrow range of size of diameter of 0.65um, and are
arranged in a face or body centered cubic bicontinuous
phase or lattice. Upon heating, the colloidal crystals
melt (Tm m470C) forming a hexagonal lamella phase. Upon
cooling the lamella phase reverses to the body or face
centered lattice.
In addition, it was found that 10 uM aqueous
suspension of Kyberdrug contains predominantly the
aggregated form as colloid crystals of a monomeric unit of
weight average molecular weight of about 1,900-2,100
daltons (99,95% w/w), and only a trace amount of the
monomeric form (0.05% w/w) at equilibrium. Moreover, the
aggregated form of the Kyberdrug dissociates into the
monomeric form at a very slow rate at pH 7.8 (20 C), which
is only influenced by the presence of Ca2+ or Mg2+ ions in
the concentration ranges of 1-25 uM in case of Ca2+, and
between 20-30 uM in the presence of Mg2+, respectively.
More specifically, as described hereinbelow,
these Kyberdrugs are isolated from individual non-
-10-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
pathogenic strains of enterobacteriaceae (e.g., E. coli)
found in mammals, including humans, using careful and
specific selection process. Starting from selected
individual bacterial cultures of mammals, the
enterobacteriaceae are obtained from mammals, e.g., humans,
which have been afflicted with infectious material, and can
be found in feces, pus, sputum, urine, skin, and the areas
of infection. Thereafter, the enterobacteriaceae are
isolated, purified, and freed from contamination like
enterotoxins, adhesions, and other unwanted toxic entero-
hemolysines including other proven pathogenic factors. The
enterobacteriaceae are validated through specific and
biochemical tests including a DNA amplification analysis of
the product by, e.g., the polymerase chain reaction.
This strain of bacteria so isolated does not
possess any endotoxins or any forms of verotoxins or
hemolysins. It does not possess genes responsible for
producing verotoxins, and does not contain activation
factors for AMP adenylate cyclase, or c-GMP Guanylate-
cyclase. It, in addition, does not contain the eae gene
sequence characteristic for EHEC or EPEC. It does not
possess the lipid A molecules described hereinabove, in its
toxic form. The bacteria producing the Kyberdrug are
unable to replicate, but contain, among other biochemical
active components, specific lipopolysaccharide-like
structures, which are responsible for the specific immune-
modulating effects in humans and animals.
The present invention relates to the production
and therapeutic application of the biological material
isolated from these non-pathogenic bacteriae (Kyberdrug),
mainly enterobacteriaceae. The Kyberdrugs of the present
invention are useful in treating infectious and chronic
-11-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
diseases as well as allergic reactions specifically and
individually in mammals. More specifically, the Kyberdrug
inhibits bacterial and viral activities. The Kyberdrug
increases the immune response and defenses. The Kyberdrug
of the present invention is useful in treating allergic
diseases, such as asthma and is effective against both DNA
and RNA viruses, including HIV-viruses, and coated and
uncoated viruses. More specifically, this biological
material isolated in accordance with the present invention
prevents adhesion of rhinoviruses to hemagglutenin ii.)
inhibits the viral neuraminidase, iii.) inhibits other
bacterial and fungal infections, and iv.) inhibits the rate
of transcription of the reverse transcriptase of
retroviruses.
The present invention is also directed to the
method of treating bacterial and viral infections in
mammals by administering effective amounts of the Kyberdrug
thereto. It has been observed that patients treated with
the Kyberdrug exhibit a decrease in the magnitude of the
allergy or asthma attacks as well as the frequency of the
symptoms, including the frequency of the seizures. This
effect has also been observed in patients suffering from
rheumatic diseases which also have been treated with the
Kyberdrug of the present invention.
The Kyberdrug of the present invention thus
inhibits bacterial and viral activities and reduces the
observed clinical symptoms. Although it possesses the
properties of the anchored lipid A properties, it does not
possess the lethal effects of free lipid A, and is devoid
of lipopolysaccharide (LPS) toxicity.
The present invention is also directed to
pharmaceutical formulations containing an effective amount
-12-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
of the Kyberdrug in association with the pharmaceutical
carrier for administration to mammals in a dose dependent
manner for successfully treating certain diseases, e.g.
viral and bacterial infections. The present invention is
.also directed to the isolated enterobacteriaceae which
produce the Kyberdrug and at the same time exhibit the
properties described hereinabove. Finally, the present
invention is directed to the process. for isolating the
Kyberdrug.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 (a) and (b) are TEM-micrographs of the
Kyberdrug.
Figure 2 is a graphical depiction comparing the
relative changes in interleuken 10(3 concentrations (pg/mL)
in serum of a patient suffering from sinusitis who is
either untreated or treated with the Kyberdrug (100 ug)
Figure 3 is a graphical representation comparing
the regulation of various interleukines in a patient
suffering from sinusitis who is either untreated or treated
with the Kyberdrug.
Figure 4 is a graphical representation of the
regulation of various interleukins stimulated by Kyberdrug
(100 ug, subcutaneously) in a large number of patients
(275) suffering from sinusitis before and after treatment
during a 4 week period.
Figure 5 (a) depicts graphically the inhibition
of HIV activity in vitro in the presence of Kyberdrug.
Figure 5(b) depicts graphically the anti-
coagulant activity as a function of concentration of
Kyberdrug at two different ionic strengths.
-13-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
Figure 6 is a diffraction pattern of the
colloidal microcrystals of the Kyberdrug isolated in
accordance with the present invention as a function of the
scattering wave vector Q at 25 C using visible light at
about 630 nm. The y axis is in units of a.u. (arbitrary
units).
Figure 7 is a diffraction pattern of the
colloidal microcrystals of the Kyberdrug as a function of
the scattering wave vector Q at 37 C using visible light at
about 630 nm. The y axis is in units of a.u. (arbitrary
units).
Figure 8A is a X-ray diffraction pattern of the
colloidal microcrystal at 25 C.
Figure 8B is a X-ray diffraction pattern of the
colloidal microcrystal at 37 C.
DETAILED DESCRIPTION OF THE PRESENT INVENTION
An aspect of the present invention, as indicated
hereinabove, is directed to the Kyberdrug and its isolation
thereof from the non-viable enterobacteriaceae, in
accordance with the present invention.
The Kyberdrugs of the present invention act,
communicate and control cellular events which are concerned
especially with antagonistic control systems in humans and
other mammals. They act like vaccines, but the Kyberdrugs
are not vaccines or like substances.
Nevertheless, the Kyberdrug inhibits bacterial
and viral infections. As is well known in the art,
bacteria and viruses are mostly responsible for chronic and
acute events, as well as inflammation, resulting from the
generation of damaging chemical radicals which interfere
with mammalian biochemical processes. The Kyberdrugs of
-14-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
the present invention inhibit the growth of infecting
bacteria and viruses and thus retard their ability to
generate these toxic chemical radicals. The Kyberdrugs
possess lytic activities towards other microorganisms or
viruses which may invade the mammal. However, the present
inventors have found that the Kyberdrugs of the present
invention are not genetic determinants. Without wishing to
be bound, it is believed that the Kyberdrug protects
against infection by directly incorporating attenuated DNA
(RNA, genes) of the infectious microorganisms or viruses,
rather than the proteins encoded by the genes. Moreover,
the specific encoded proteins and enzymes are inhibited by
the Kyberdrug.
The Kyberdrug is a large molecule. Studies of
the hydrodynamic properties of the Kyberdrugs by means of
inelastic light & static scattering experiments have shown
that the Kyberdrugs are almost spherical in shape, having a
hydrodynamic radius of < RH > = 0.45 - 0.65 lam, which is
almost insensitive to changes in ionic strength and
temperature, even at very low concentrations thereof. This
finding is of some importance since it generates a constant
physical measure during production, and permits the
determination of the concentration of the Kyberdrugs easily
by measuring either size or masses through transmission
absorption spectroscopy at 550 nm, or by using a light
scattering detector. This is in contrast to the average
hydrodynamic radius of viable E.Coli which is of the order
of 6.2 pm, and has a rather large size variation of almost
50% depending on the nutritional and growth state of the
E.Coli bacteria. In other words, the E.Coli are more than
ten times larger than the Kyberdrug! Moreover, the
production of Kyberdrug does not depend on the growth rate
-15-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
and nutritional, state of the production of the bacteria,
especially since the replicating properties thereof are
abolished. MALDI-TOF-mass-spectroscopy and LC-MS-
analyses of this material provided a molecular mass of
approximately 1,900 (MZ + Na)', indicating the absence of
any proteinaceous components, e.g. oligopeptides,
oligonucleotides or nucleosides or derivatives of
peptoglycans or muramyl peptides including those of N-
acetyl-muramyl-L-alanyl-D-isoglutamine, normally referred
to as muramyl dipeptide (Mr= 459). However, the Kyberdrugs
aggregate in a concentration dependent manner in aqueous
solutions in the presence of NaCl or EDTA (0.9% w/w)
resulting in the large hydrodynamic radius of < RH > = 0.45
- 0.65 pm which is equivalent to a molar mass of 120,000 to
150,000 daltons having apparent aggregationals numbers of
68 - 80, even at Kyberdrug concentrations as low as 10
pg/mL. Thus, in aqueous solutions, it has a molar mass of
about 120,000 to about 150,000 daltons.
The Kyberdrug is not a,protein nor does it
contain proteinaceous material. Moreover, it is not a
nucleic acid. It is therefore not a glycoprotein nor a
lipoprotein. In aqueous solutions, it consists of
aggregate units of a monomer. The monomer has a molecular
weight of about 1900-2000 daltons, while the aggregate has
a molecular weight of about 120,000-150,000. Upon
sonification or other methods of dissociation, the
aggregate disassociates into the monomer, which is isolated
and which as indicated hereinabove has a molecular weight
of approximately 1900-2000 daltons.
The Kyberdrug is a lipopolysaccharide. The
monomer contains an amino hexose. The sugar ring, contains
-16-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
from 6-12 carbon atoms and more preferably 8-10 carbon
atoms. The sugar ring is a furanose. The sugar in the
Kyberdrug is predominantly glucose, although galactose has
also been found to be present in the Kyberdrug. It
possesses bactericidal action, especially against
mycobacteria, e.g., Nocardia.
When the Kyberdrug is isolated in an aqueous
solution, it forms an aggregate and is believed, without
wishing to be bound, to consist of at least 60-80 monomers
per particle size of 0.3uM in radius. The Kyberdrug has a
constant diameter of 0.65uM at constant chemical potential
with a fairly small dispersion (5) of 10-15% only. The
size variation (5) of the Kyberdrug at _ionic strength of
0.153 M NaCl at constant pH (of 6.9) and temperature does
not change significantly when raising the ionic strength to
0.300 M NaCl. However, a shrinkage of the hydrodynamic .
radius has been noticed as measured through inelastic light
scattering experiments. A change from about 0.65uM at 0.350
M NaCl (20 C) to about 0.57 0.06uM at 0.350 M NaCl (20 C)
has been found, which is reversible upon changing the salt
concentration back to the initial concentration. Moreover,
below 0.153 M NaCl (20 C), the Kyberdrug expands to about
0.70 0.08 uM at 0.015 M NaCl, which is reversible too.
The Kyberdrugs are composed of a plurality of
colloidal crystals. Without wishing to be bound, it is
believed that the many colloidal crystals are stabilized
and separated through strong electrostatic forces,
hydrodynamic interactions brought about by its unique
chemical structure and the ionic strength of the solution
at ambient temperature. The Kyberdrugs have either a face-
centered cubic (fcc) crystal lattice or body centered cubic
(bcc) lattice, and they are interchangeable under
-17-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
appropriate conditions. For example, when placed in a
dilute salt solution, e.g., 0.07% NaCl, a crystal lattice
in the fcc is transformed to a crystal lattice in the bcc
form.
The Kyberdrug of the present invention is an
aggregate of the modified form of lipid A or the
lipopolysaccharide containing the modified Lipid A
molecule. Lipid A consists of a backbone of ((3-1,6)-linked
D-glucosamine dissaccharide which carries phosphate
residues in positions 1 and 4' and amidate or esterified
long chain fatty acids (generally D-3-hydroxy and/or
acyloxy fatty acids) in each of the possible sites in the
glucosamine moieties.
The modified lipid A molecule, collected and
isolated in accordance with the procedure described
hereinbelow contains:
i) a reducing sugar end, where the sugar is a
hexosamine, mainly N-acylated D-glucosamine or D-
galactosamine, respectively; and there are two sugars to
the hexosamine present per monomeric unit of molecular
weight of about 1,900-2,100;
ii) an ester linkage and/or a peptide linkage;
these linkages are believed to arise from the condensation
of the amino group of the hexamine with a carboxy group of
a fatty acid;
iii) fatty acids of (R)-3-hydroxytetradecanoic
acid having a free unesterified R-3-hydroxy group;
iv) an esterified (R)-3-hydroxytetradecanoic acid
fatty acid residue, which is esterified with another
saturated fatty acid at the R-3-hydroxyl of the (R)-3-
hydroxy-tetradecanoic acid of chain lengths of n=12 and or
n=14; and
-18-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
v) no phosphate group or one phosphate group per
monomeric unit of the Kyberdrug of monomer molecular weight
of about 1,900 to about 2,100 daltons.
These characteristic chemical features are
obtained from either mild acidic or alkaline hydrolysis
with subsequent GC-MC determinations through chiral
capillary columns, MALDI-TOF-MS in the presence of a
suitable matrix, and specific enzymatic attack with acyl
specific hydrolases or N-acyl-amidases in apolar solvents
in the presence of 0.01% (v/v) water, respectively. The
absolute R or S configuration was also determined by means
of optical rotation of the isolated enantiomers of 3-
hydroxy-tetradecanoic acid of chain lengths of n=12 and or
n=14 in additional to chiral GC-MS techniques by comparing
the enantiomers with those obtained through asymmetric
synthesis including NMR spectroscopy in the presence of a.
suitable phase shift reagent.
The Kyberdrugs of the present invention are lipid
A molecules containing predominantly no phosphate groups at
either position 1 or 4' in the aggregate (hereinafter also
known as modified Lipid A). This modified form of lipid A
of the present invention, however, does contain a minimal
amount of phosphate groups. The modified lipid A molecule
(Kyberdrug) has a very low phosphate content. More
specifically, it consists of at least about 80% (w/w) of
non-phosphorylated lipid A analog and at most about 20%
(w/w) of a mono-phosphorylated lipid A analog. An Example
of monophosphorylated modified lipid A molecule has the
structure:
-19-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
II H --- C 1-12
OH 0 O
NH 0 NH
-0 OH
OR
HFtH HHH
H H
H H H
HHH HHFi
wherein
0
11
R and R' are independently hydrogen or O-P-.
OH
However, when formed in the aggregate, in at least 80%
(w/w) of the aggregate, R and R' are hydrogen, and in at
most 20% (w/w) in the aggregate, one of R and R' is
hydrogen and the other is phosphate. But, a minimal
amount, if any, of the monomer is found wherein both R and
R',are phosphate.
The amount of monophosphorylated lipid present in
the aggregate varies, depending on the patient, including
the illness from which the Kyberdrug has been cultured and
finally isolated in accordance with the procedure described
hereinbelow. In addition, the monophosphate may be present
on the monomer at the reducing end of the sugar, which is
the 1-0-P03- or the non-reducing end of the sugar, i.e., 4'-
-20-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
O-P03-, leaving the reducing end free and active. However,
a small fraction of the diphosphorylated form at 1-position
(reducing end sugar I) and at the 4' (non-reducing end,
sugar II) of the dissaccharide moiety has also been
isolated. However, no pyrophosphate derivative at either
end has been found.
The Kyberdrug sugar amine, is predominantly a
glucose amine with an amine moiety (NOH) substitute at C-2
and C-2' of the pyranose ring. The molecule does not
contain an amine, however, for it forms part of an amide
bond with a fatty acid, which fatty acid contains an even
number of carbon atoms ranging from a total of 12 carbon
atoms up to a total of 36 carbon atoms and more preferably
from a total of 14 carbon atoms up to a total of 30 carbon
atoms, wherein the R carbon to the carboxy group is
substituted with a hydroxy group that has been esterified.
with a fatty acid of 10-20 carbon atoms, and more
preferably, from 12-18 carbon atoms. It is most preferred
that the size of the substituent on the 2 and 2' positions
range from about 22 to 36 carbon atoms and more preferably
from about 24 to 30 carbon atoms. It is preferred that the
fatty acid is 3- hydroxy- tetradecanoic acid. However,
whatever amide is present can be chemically modified by
chemical reactions known in the art e.g., hydrolysis of
the peptide followed by the reaction of the free amide with
the desired fatty acid. Obviously, protecting groups known
in the art may be utilized to protect the groups on the
molecule which are reactive under the reaction conditions.
If the phosphate groups that are normally present
on lipid A at C-1 and C-4' are not present, they are
replaced in the modified lipid A molecule by OH groups.
The hydroxy group at the 3 and 3' position of the ring may
-21-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
be esterified with fatty acid containing 12 to 36 carbon
atoms and more preferably from 14 to 30 carbon atoms
wherein the R carbon to the carboxy group is substituted
with a hydroxy group or a hydroxy group esterified with a
fatty acid containing 10-20 carbon atoms and more
preferably from 12-18 carbon atoms. It is more preferred
that when the 13 carbon atom on the 3 or 3' position is
substituted with a hydroxy group, the size of the
substituent on the 3 and 3' positions thereon independently
ranges from 10 to 20 carbons and more preferably from 12 to
18 carbon atoms. On the other hand, if the (3 carbon has a
hydroxy group esterified to the fatty acid, the size of the
substituent on the 3 or 3' position each independently
contains 22 to 36 carbon atoms and more preferably 24 to 30
carbon atoms. It is most preferred that the fatty acid is
3-OH-tetradecanoic acid. The other positions, i.e., 4 and
6' are substituted with a hydroxy group. It is to.be noted
that the fatty acids of the lengths indicated hereinabove
may replace those found on the isolated Kyberdrug by
chemical transformations known in the art, such as by
transesterifications, utilizing the desired fatty acids and
the appropriate protecting groups known in the art.
It has been found that the monomer contains an
even number of fatty acid moieties (either esterified or
linked via an amide linkage) per monomer. Thus, the
monomer may contain two, four or six fatty acid moieties.
As explained hereinbelow,-the lipid A molecules
described hereinabove are isolated from non-viable
enterobacteriaceae. Thus, the present invention
contemplates the various variations of the lipid A
molecules described hereinbelow that are naturally present
in the viable enterobacteriaceae.
-22-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
In addition, the Kyberdrug has the following
characteristics:
(a) They contain a substantially constant
hydrodynamic radius of about 0.3 to about 0.40 }1M having a
low polydispersity index of about 0.05 to about 0.08%.
(b) The monomer molecular weight is about 1900 to
about 2000 daltons.
(c) Aggregational numbers are between about 68 to
about 75 for the Kyberdrug, and are almost constant with
temperature, only slightly dependent on ionic conditions.
(d) The Kyberdrug has a number weight molecular
weight of about 130,000 9,000 daltons, a weight average
molecular weight of about 135,000 6,700 daltons and an
average molecular weight of about 137,000 10,700 daltons.
(e) The Kyberdrug contains two sugars per
monomer, predominantly two glucosamines, although it may
contain one glucosamine and one galactosamine.
(f) It contains inorganic phosphate, which is
believed to be bound to one of the glucosamine molecule
with the monomer of the Kyberdrug.
(g) The Kyberdrug contains 3-hydroxytetra-
decanoic acid, but no 2-hydroxy fatty acids.
(h) The 3-hydroxytetradecanoic acid is in the R-
configuration.
(i) There are most likely an even number of the
3-hydroxy tetradecanoic acid per monomer of Kyberdrug,
e.g., two, four or six.
(j) The isolated Kyberdrugs are colloidal
crystals.
(k) The shape of the colloidal crystals, which
resemble a liquid like material, can be arranged in the
form of hollow spheres having a diameter of about 0.6 uM.
-23-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
These hydrodynamic forms act as little osmometers depending
on various factors, such as*counterions, pH and
temperature. The pH of the solution in which the Kyberdrug
is isolated is critical since at alkaline pH such as pH=7.5
or greater these aggregates can grow to huge aggregate
having molecular weights of 1.17 x 107daltons or higher.
This aggregation is reversible when the pH is lowered to
6.5. The huge aggregates are rather flexible, and
connected through a hinge to yield a sort of tabular
structure where each tubular structure has a tubular
diameter of approximately 110 nm.
(1) The stability of the Kyberdrug in saline
solution, e.g., 0.154 M NaCl as colloidal crystals is
enhanced in the presence of about 5-10 nM Ca2+, as
determined by UV/VIS-spectroscopy at 550-600 nm at 20-35 C.
(m) The monophosphorylated (20%) form within the
Kyberdrug can be added to the non-phosphorylated form in
the form of salts, e.g., Group I salts, such as sodium,
potassium, ammonium, as well as the calcium and/or
magnesium salts in an equivalent way. Other salts which
could also be used include the nitrogen containing salts of
choline, phosphocholine, L-lysine, L-arginine, L-histidine
and L-proline. In addition, the following naturally
occurring sulfur containing compounds can replace the
salts:
(a) L-cysteine
(b) L-methionine
(c) S-(+)-adenosylmethionine.
(n) The Kyberdrug can be non-covalently bonded to
human serum albumin (HSA) as well as to L-polylysine or L-
polyarginine (MW 9000-1000).
-24-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
The Kyberdrugs or modified lipid A molecules
isolated from the non-viable enterobacteriaceae in
accordance with the present invention are substantially
pure. It is preferred that the Kyberdrug is at least
about 75% pure and more preferably that it is at least
about 80% and even more preferred that it is at least about
85% pure and most preferred that it is at least 90% pure.
Although some of the modified A molecules may have the core
carbohydrates of the oligosaccharide as the L-isomer, the
preferred embodiments have the core carbohydrates
substantially as the D isomer. It is preferred that at
least about 75% of the carbohydrates present is in the D
isomer, more preferred that at least about 80% of the
carbohydrate is in the D isomer, even more preferred that
at least about 85% of the carbohydrate present in the D
isomer, and especially preferred that at least about 90% of
the carbohydrate present is in the D isomer and more
especially preferred that at least about 95% of the
carbohydrate present is in the D isomer and most preferred
that all of the carbohydrate present is in the D isomer.
The Kyberdrugs of the present invention are
isolated from non-viable enterobacteriaceae. The starting
enterobacteriaceae from which the non-viable
enterobacteriaceae are obtained generally are found in
feces, pus, sputum, urine,.skin or sites in the mammal,
e.g., human, at which the enterobacteriaceae have infected.
The starting enterobacteriaceae may be obtained from any
Enterobacteriaceae, including parent organisms and mutants
which are present at the sites indicated. By way of
example, the following genera are illustrative of the type
of organisms that may be utilized as starting
enterobacteriaceae: Salmonella, Shigella, Escherichia,
-25-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
Brucella, Bordetella, Citrobacter, Pseudomonas, Pasturella,
Neisseria, Proteus, Klebsiella, Serratia, Bacterioides,
Bacillus, Carnobacterium, Caulobacter, Clostridium,
Corynebacterium, Enterobacter, Halobacteria, Lactobacillus,
Lactococcus, Leuconstoc, Listeria, Micrococcus,
Mycobacterium, Pedioccoccus, Propionibacterium, Sarzina,
Serratia, Staphylococcus, Streptococcus and Vibro. The
following species may be employed: S. minnesota, S.
typhimurium, B. pertussis, B. - abortus, S. enteritidis, E.
coil, S. typhi, S. marcescens, S. typhosa, Shigella flexni
and S. abortus equi, and the like, E.coli and Shi gella are
the most preferred enterobacteriaceae utilized.
The enterobacteriaceae of the present invention
which produce the Kyberdrug, and from which the Kyberdrug
is isolated, are isolated by the present process. These
bacteria produce proteinaceous compounds that are lethal
against other bacteria. More specifically, these bacteria
produce compounds which exhibit antagonistic activities
against other bacteria, retroviruses and coated and
uncoated viruses, but not against themselves. They possess
all the antigenic components for exerting antigenicity,
including immune-stimulating effects, without having the
deleterious effects of endotoxins mediated bacterial
translocation through the gut. Moreover, and most
importantly, they are unable to replicate (to grow).
Moreover, the non-viable enterobacteriaceae do not carry
genetic determinants which are necessary for self-
replication. Since the enterobacteriaceae are devoid of
any phage-like lytic.activities, but reveal certain
bacteriocin like activities as well as some kind of
lysogeny, these bacteria which produce the Kyberdrug have
the advantage of being specific in a broad sense, since
-26-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
they have bacteriocin-like activity coupled with lysogeny.
In addition, these bacteria induce subsequent colicin
production, and are immune to infections from their
corresponding original E. Coli or enterobacteriaceae from
which the Kyberdrugs have been obtained.
Furthermore, the non-viable enterobacteriaceae
from which the Kyberdrugs are obtained are of
enteropathogenic serotype (EPEC), so localized adherence to
the intestine resulting in cupping of the enterocyte and
destruction of microvilli are avoided. In addition, the
enterobacteriaceae are also devoid of enterotoxigenic
E.Coli (ETEC), the entero-invasive E.Coli (EIEC) and the
enterohemmorhagic E.Coli (EHEC).
The enterobacteriaceae utilized as starting
enterobacteriaceae as well as the non replicating
enterobacteriaceae may be gram-positive; it is preferred,
however, that the enterobacteriaceae are gram-negative.. It
is also preferred that they are aerobic enterobacteriaceae.
It is even more preferred that both the starting
enterobacteriaceae and the non-viable enterobacteriaceae
are rod-shaped. It is even more preferred that the
starting and non-viable enterobacteriaceae contain the
enzyme 3-D-glucuroindase which reveals the fluorophore
umbelliferon which is used as an indicator for successful
culturing.
The non-viable enterobacteriaceae from which the
Kyberdrugs are isolated possess the following properties:
(a) it is not viable; i.e., it is unable to grow
or replicate.
(b) it does not have the ability to convert
hydroxy coumarin-7-glucoside (also known as umbelliform-7-
glucoside) to umbelliforme, which is a 7-hydroxy-2H-1-
-27-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
benzo-pyran-2-one also known as hydroxy coumarine). As
used hereinafter, this reaction will be identified as the
MUG Reaction. This is determined by a standard assay,
known to the skilled artisan. See "Fluorogenic and
Chromogenic Substrates used Bacterial Diagnostics" by M.
Manoti, et al. in Microbiological Reviews, 55(3), 335-348
(1991), the contents of which is incorporated herein by
reference.
(c) it is unable to convert tryptophan to indole
(hereinafter referred to as the indole reaction), as
determined by a standard assay, which is known to one of
ordinary skill in the art.
(d) it has bactericidal action especially against
mycobacteria. As used herein, "mycobacteria" are a genus
of aerobic, gram-positive bacteria that are present in
soil, water and tissues of various animal. They include
the causative agent of tuberculosis and liposy. An example
thereof is Nocardia.
(e) it possesses the colicin factor, i.e.,
bacterial plasmids that permit the organisms to produce
colicins, which are a group of proteins produced by certain
strains of Enterobacteriaceae, that are bactericial for
certain strains of the same family.
(f) it lost the ability to produce hemolysins, an
antibody that causes hemolysis.
(g) it cannot produce endotoxins, i.e., a toxic
lipopolysaccharide released from the cell of gram- negative
bacteria upon destruction of the cell.
(h) it cannot produce verotoxin in any form,
neither the heat insensitive form nor the heat labile form.
-28-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
(i) it does not possess any activation factors
for producing c-AMP adenylate-cyclic or cGMP guanylate-cyclase.
(j) it does not have adhesion molecules such as
ICAM I-III and does not permit viruses to adhere to cell
walls.
(k) it does not have the eae gene sequence,
characteristic for EHEC and EPEC.
(1) it is rod shaped.
(m) they belong to the class of Rough (R), smooth
(S) or mucoidal forms (m), devoid of any hemolysine active
material.
Using some or all of these identification
factors, the non-viable enterobacteriaceae can be selected
from other bacteria that are grown as described herein.
The Kyberdrugs of the present invention are
prepared using standard microbial techniques of isolation
of enterobacteriaceae strains from infected areas of
mammals, including humans, selecting those strains which do
not contain endotoxins, as determined by standard assays,
and culturing and growing these strains, heat treating the
selected strains at temperature and time sufficient to
denature bacteriocins that may be present, extracting the
Kyberdrug therefrom, and then lyophilizing and purifying
the resulting product. it should be noted that the
lyophilization step may precede the purification step or
vice versa.
As described hereinbelow, the enterobacteriaceae
are subjected to various assays, identified hereinbelow,
which are used to select the appropriate species, and these
are incorporated into the automatic VITEK system to verify
that homolysine negative strains, e.g., citrobacter or
Salmonella, respectively are absent. If they are present,
-29-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
these strains should be subsequently eliminated through
continuous culturing and further analysis with VITEK.
These specific microbiological assays are all
being applied to exclude pathogenic material originating
from pathogenic microorganisms. Particularly, the
combination of these sensitive assays, including the indole
and MUG reactions ensures that only E. Coli bacteria and
other non-toxic bacteria are being selected and identified.
.During the selection steps, various assays are
performed to verify that the correct strain is being
isolated, and that the bacteria selected do not possess
pathogenic material. Some of the assays test for the
presence or absence of two enzymes that are present in
enterobacteriaceae capable of producing endotoxins. They
are tryptophandesamine and 3-glucuroindase. The (3-
glucuroindase catalyzes the MUG reaction, described
hereinabove. Trytophanase (tryptophansesaminase) in E.
Coli catalyzes the deamination of L-tryptophase to indole,
pyruvic acid and ammonium. This is possible if the
microorganism is capable of producing L-tryptophase through
its own gene, which in this case is characteristic of the
enterobacteriaceae, particularly E. Coli. In addition, the
addition of this enzymatic activity indicates the
colinearity of this specific gene, and disregards any
mutants which could be present in the enterobacteriaceae,
especially, E. Coli. Those strains which give a positive
test are maintained, while those which do not have those
enzymes are discarded.
The presence of these enzymes is determined by
standard assays known by one of ordinary skill in the art.
A standard assay for the presence of 13-
glucuroindase is described in G. Dahlen, et al., App.
-30-
CA 02436107 2009-07-31
Microbiol., 26, 863-866 (1973); S.C. Edberg, et al., J.
Clin. Microbiol., 24, 308-371 (1986); Kasper, et al., Appl.
Environ. Microbiol., 53, 1073-1077 (1987)õ
Any assay for determining if tryptophendesaminase
is present may be utilized. These are known to one of
ordinary skilled in the art. For example, this may be
determined using the indole reaction described hereinabove.
Another assay which is used for verifying the selection of
the correct strain is the MUG Reaction Assay, referred to
hereinabove, in which hydroxycoumerin-7 -glucoside (also
known as umbelliform-7-glucoside) is converted to
umbelliforme. The procedure is described in "Fluorogenic
and chromogenic substrates used in Bacterial Diagnostics",
by M. Manofi, et al., in Microbiological Reviews, 55(3), 335-348 (1991).
The indole assay is also used for verifying that
the correct strain is chosen. In the indole assay,
tryptophan under the conditions described therein is
converted to indole.
Another test which may be used is colicin
determination. Colicins are a group of proteins produced
by Enterobacteriaceae, that are bactericidal to other
strains of bacteria of the same family. The enterobacteria
isolated in the various steps have bactericial action
against various bacteria including mycobacteria, such as
Nocardia and the like. Thus, those strains which show a
positive result from this assay are the strains which are
desired, while those exhibiting a negative effect are
discarded.
-31-
CA 02436107 2009-07-31
Another assay which is used to select the correct
strain of enterobacteria tests for the presence or absence
of adhesion factors and enterotoxins. These can be
detected using the polymerase chain reaction. (PCR) assay,
which is described by B. Schutz, et al. in Lab Med., 17,
496, 1993.
It is a well known screening procedure, which
takes into account the various toxin types and subtypes
occurring in man. More specifically, synthetic
oligonucleotide primers complementary to the DNA sequence
for the endotoxin genes, e.g., LTI, STI, VTI and VTI1 are
prepared. The genomic DNA is isolated from the bacteria;
if DNA polymerase denatures the genomic DNA and elongates
the primer, then it is concluded that the strain contains
the endotoxin. Those strains are discarded. If there is
no reaction, then the strain cannot make endotoxin and it
is maintained.
It is to be noted that the enterobacteriaceae
that are collected and further harvested give positive
results in all of the above assays, except in the colicin
test, where it gives a negative result. It should also be
noted that no one assay is determinative if the proper
strain is collected, but the more assays that are performed
which provide the appropriate results, the greater is the
probability that the proper strain is collected.
Nevertheless, it is preferred that prior to continuing the
isolation process described herein, that the desired
results are obtained from at least two of the above-
identified assays. Moreover, after each harvesting step,
as explained hereinbelow, at least two assays should be
performed to assure that the selected strain has not been
contaminated with other undesired bacteria.
-32-
CA 02436107 2003-04-04
WO 02/28424 PCT/IB01/02284
The Kyberdrugs are prepared by applying standard,
though controlled, microbial techniques of isolation of
selected enterobacteria strains from human individuals,
suffering from certain diseases, e.g., cough and cold,
rheumatism, osteoarthritis, herpes simplex infection, HIV-
infection or a serious staphylococcus infection and the
like with their destructive side effects, then culturing
and identifying the microbial strain, and subsequently
culturing the strain and discriminating the desired
colonies from contaminated bacterial strains which are
unwanted and therefore eliminated. The general procedure
is exemplified in Scheme I, which is attached hereto in the
Appendix.
A sample from the infected area of the mammalian
host is collected by standard techniques and the bacteria
thereon are inoculated on Agar, containing nutrients
typically used to grow and harvest bacteria, such as solid
growth media. Typical nutrients include amino acids and
sample carbohydrates. The bacteria are grown at about 37 C
for at least about 12-18 hours; then the colonies are
isolated. Bacteria samples from each of the colonies are
subjected to various assays, such as those described
hereinabove, for the determination of the presence of
colicin, and absence of endotoxins. In addition, assays
are performed to determine the presence or absence of 13-
glucuroindase and tryptophendisaminase, such as by the MUG
reaction and indole reactions, respectively. More
specifically, those colonies which undergo lactose
utilization and have negative MUG and negative indole
reactions and do not possess tryptophendisaminase or R-
glucuroindase , and which have a positive colicin test, as
-33-
CA 02436107 2009-07-31
determined by standard assays such as those described
hereinabove, are isolated.
The selected bacteria are recultured on
Microtiter plates, preferably 96-well, with saccharose.
They are harvested at effective harvesting temperatures for
sufficient time to colonize, preferably for 18-25 hours at
about 37 C. Optionally, but preferably the strains are
assayed to ensure no new mutations have occurred; thus
assays known in the art to verify that the bacteria
isolated are non-toxic enterobacteriaceae strains are
conducted. Such assays include but are not limited to the
standard assays described hereinabove, such as the MUG
assay, the tryptophendesaminase assay, the PCR assay, and
the colcinin assay, and the like. If all of the strains
give negative results in all of the tests, except the
colcinin test, and if the colcinin test is positive, then
these process is continued. If, on the other hand, they
give positive results in any of the above-identified tests
(except the colicin assay) or give negative results in the
colicin assay, then culturing is restarted or a new sample
is obtained and the procedure followed as above.
The strains are identified by techniques known in the art,
such as through the use of VITEKTM, a well known
automative system used by the ordinarily skilled artisan
for identification of clinical relevant strains and
determination of resistance. VITEK is an automated assay
system used in clinical microbiology, capable of
identifying significant gram-positive and gram-negative
bacteria and yeasts and performs antimicrobic
susceptibility tests. The use of VITEK is described in an
article in "Automation in Clinical Microbiology", by C.C.
Pierson & K.D. McClatchey, in "Encyclopedia of
-34-
CA 02436107 2009-07-31
Microbiology", Vol. 1, pp. 171-179 (1992), Academic Press, ed. by J.
Lederberg. The
VITEK automated system is commercially available, for example, it is sold by
BioMerieux Vitek, Inc. in Missouri. Using the VITEK, those strains which are
unidentified are then eliminated.
The selected strains are then cultured and
harvested using techniques known in the art. It is
preferred that they are harvested on agar containing the
essential nutrients, e.g., a sugar (e.g., glucose) and
amino acid(s) (or protein) containing sulfur and grown for
sufficient time to colonize at temperatures effective for
growth and replication. It is even more preferred that the
strains are cultured on an endo-Agar or Diagonal Agar resin
containing nutrients commonly used for growth under
conditions effective for growth and for a time sufficient.
for growth to be observed. The preferred media and
nutrients are depicted in Table I and the most preferred
are depicted in Table II, which is in the Appendix attached
hereto. It is preferred that the nutrients contain protein
and sugar (e.g., glucose) and salt and optionally vitamins,
including Vitamins B, e.g., B6, B1 and B12 and the like and
water soluble vitamins, and sulfur-containing amino acids,
such as cysteine, cystine or methionine, yeast extracts and
water. It is preferred that they be grown for 18-24 hours
at 37 C.
The endo-Agar is considered a very selective
resin, particularly for gram-negative aerobic
enterobacteriaceae, and especially for those of rod-shaped
nature. The preferred strains grown are the strains that
contain B-D-glucuroindase such as E.Coli or Shigella, since
-35-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
the enzyme is useful in revealing the fluorophore
umbelliferon, which can be used as an indicator.
Another way of culturing'small and large amounts
of the appropriate strain is through the use of solid Endo-
Agar or Diagonal Agar in the additional presence of oxygen
at about pH 7.0 and about 30 C, preserving the cell-bound-
bacteriocins, e.g., colicin in the case of E.Coli, or the
intra-cellular bound column like material.
Alternatively, the identified strains are grown
using standard techniques known in the art. For example,
they can be grown in bioreactors under sterile conditions
using normal media utilized by one of ordinary skill in the
art, e.g., broth, for growing for E.Coli bacteria.
It is preferred that the selected bacteria are
cultivated on a bouillon medium in a bioreactor at
effective harvesting temperatures for an effective amount
of time to colonize, e.g., at 37 C, for about 12-18 hours.
A bioreactor is more efficient, and the bacteria grow
faster in a bioreactor than on agar. The broth media can
have pH ranging between 6.5 to 7.5. Although agar media
can be used, as in the previous harvesting step, the
bouillon media is preferred at this stage since the growth
of the proper strain is significantly faster than on the
agar media and since most of the proper strains of
enterobacteriaceae have been selected.
The selected strain and harvested colonies are
next cultured on Diagonal Agar Resin containing the
nutrients of Table I and more preferably in Table II for an
effective amount of time to harvest same at effective
temperatures. It is preferred that the strain are
incubated at about 37 1.0 C for about 12-18 hours.
-36-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
Preferably, the bacteria are cultivated on
Diagonal Agar under effective harvesting conditions, for a
time sufficient to grow the bacteria. When grown on the
Diagonal Agar, the bacterial shell is formed or has been
formed. Normally, the bacteria are stored between 5-10 C
on Diagonal Agar (Solid growth media). These bacteria
either do not replicate or if they do replicate, they
replicate at a slower rate than prior to this step. In
addition, the action by the Col' E. coli (that is, E: coli
containing colicin) grow only on solid growth media.
To assure no cross contamination, it is
preferable that the strain is assayed using standard
techniques known to one of ordinary skill in the art to
verify that the strain is enterobacteriaceae which contain
minimal amounts, if any, of toxins. As used herein, by the
use of the term "minimal", it is meant that the strain
contains no pathogens or if toxins are present, that they
are present in amounts which are not detected by the PCR
assay described hereinabove. Thus, it is preferred that
the cultivated bacteria on the agar be tested to determine
if toxins are present. If the result from the assay is
negative, then the process for preparing the Kyberdrug
should be continued, otherwise, if positive, then the
strain should be discarded.
Deviation from the above protocol or changes in
pH, temperature or addition of nutrients to growth media,
particularly sulfur containing amino acids such as (+)-S-
adenosylmethione or yeast extracts containing water soluble
vitamins, affects the amount of Kyberdrug and the ease of
selection and further purification of the material. The
ordinarily skilled artisan, however, can easily determine
the appropriate conditions for the growth of the
-37-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
enterobacteriaceae. However, the most preferred media are
those tabulated in Table 2 in the Appendix, for these tend
to maximize the production of colicin-like material
(bacteriocins), especially when selected cells are
propagated in broth at constant pH 6.5. Furthermore, the
synthesis of intracellular and/or extracellular bacteriocin
like material is inducible when using solid Agar. In the
latter case, extracellular bound proteinacious material is
released into the broth, while intracellular bound material
remains with the selected microorganism production of
bacteriocin-like material and is induced by exposure of the
selected microorganism to media containing mitomycin C or
UV light in the presence of oxygen. The inventors estimate
that about 30-35% of the E.Coli strain obtained from the
feces of a patient suffering from osteoarthritis or chronic
rheumatism, and then grown in the presence of L(+)cysteine
or L(-)methionine, respectively in the presence of 02 and
mitomycin C, is colicin positive (col+).
The genes encoding for colicin or colicin-like
material including bacteriocins are almost exclusively
located on coplasmids which are easily transmissible to
other similar strains belonging to the family of
Enterobacteria by such methods as conjugation or cell to
cell contact. However, in the present culturing and
selection, the activity of colicin and bacteriocin like
material is effective against a small range of cultures of
Enterobacteria.
The cultured strains are able to protect the
bacteriocin-like producing strains from their own toxic
metabolites. Maximum expression of the proteins
responsible for the immunity occurs when the strains are
grown via a non-inducing mechanism e.g., in the absence of
-38-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
mitomycin C, but in the presence of sulfur containing amino
acid or yeast extract, water soluble vitamins and-oxygen.
However, expression of these protein compounds also occurs
when only a small percentage of the bacteriocin-producing
cells are producing bacteriocins; under these conditions,
substantially all of the cells reveal evidence of producing
free immunity protein. The regulation of these inhibitory
system is constitutive and under the direction of the
appropriate immunity determining plasmid, respectively.
.The selected bacteria at this stage do not
contain any replicating machinery. Their properties are
tabulated in Table III, in the appendix. However, without
wishing to be bound, it is believed that they still contain
the LEX A protein which is responsible for preventing
continuous synthesis of enzymes that repair damaged plasmid
DNA and colicin or colicin-like material, respectively.
Due to the selection of the bacteria in accordance with the
present invention, especially those bacteria which were
grown in the presence of oxygen and in the presence of
sulfur containing amino acids including the Endo-Agar at pH
7.0, it is believed no repair process of DNA and synthesis
of enzyme specific for DNA biosynthesis is possible; hence
the replicating process is inhibited. The formerly present
DNAs and RNAs degrade due to the enhanced activities of the
DNAse and RNAse, respectively.
Without wishing to be bound, it is believed that
the expression of the operon in growing cells e.g. E.Coli,
is controlled by the SOS system that regulates error-prone
DNA repair in these specified bacteria. SOS regulation
involves the LEX A protein and REC protein, respectively.
Furthermore, the operon promoter which is a very strong
candidate for pore-forming colicins or bactericins,
-39-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
respectively, contains a LEX operator sequence consisting
of two overlapped SOS boxes to which LEX A protein binds,
preventing synthesis of enzymes that repair damaged DNA.
Moreover, it is believed that the LEX A protein prevents
the biosynthesis of colicin-like material and lysis
proteins. It is believed that exposure to either DNA
damaging agents or inhibitors of DNA replication results in
the generation of an induced signal (mitomycin C)
responsible for reversible activation of the REC A protein
to its protease, respectively. The activated REC A protein
then cleaves the LEX A repressor, resulting in the de-
repression of the SOS regulated genes, subsequently leading
to a production of the bacteriocin-like and lysis proteins.
So overproduction of lysis protein may result in early cell
death, but this seems to be regulated through the immunity
gene which is apparently orientated in the opposite
direction of the structural and lysis genes, and is not
under the control of the SOS. Apparently, this regulator
which includes the SOS system can be influenced in this
case by the presence of a glucose medium, sulfur containing
amino acids and/or the presence of yeast extracts in the
presence of oxygen, since colicin production is reduced.
So the regulator must be bound to the promoter region for
transcription to occur, which is inhibited by the
aforedescribed process. Thus, the nutrients available help
regulate metabolic activities. Moreover, under the
culturing conditions of the present process, replication is
inhibited and template carrying DNA fragments are not
available; thus the cells apparently shrink considerably,
and release the before anchored outer lipooligosaccharides
(Kyberdrug) having sizes of 0.6 pm in hydrodynamic
radius, when subjected to rinsing, as in the next step.
-40-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
The selected strain is then -rinsed with aqueous
solution and more preferably saline solution or phenol.
For example, the selected strain may be rinsed with dilute
saline solution or phenol solution. It is preferred that
the concentration of the saline solution is less than about
2% (w/w) and more preferably less than 1.5% (w/w); and even
more preferably less than about 1% by weight. It is
preferred that the concentration of the saline solution
ranges from about 0.5% (w/w) to about 1.5% (w/w) and more
preferably from about 0.7% to about 1.1% by weight and more
preferably at about 0.9% saline solution.
A preferred dilute phenol solution has a
concentration ranging from about 0.01% to about 1% (w/w)
and more preferably from about 0.1% to about 0.5% (w/w) and
most preferably at about 0.25%. The gentle rinse of the
product forms the preformed Kyberdrug.
The last step is killing, that is, destroying the
bacteria. This is effected under mild conditions using.
techniques known to one of ordinary skill in the art, such
as by heat treatment, radiation, subjecting the bacteria to
extreme pH's, proteolysis and the like. It is preferred
that the bacteria is killed by subjecting the "bacteria" to
a heat treatment under conditions sufficient to kill the
bacteria and denature any protein present. Preferably, the
inactivation is conducted at temperatures greater than 60 C
and more preferably greater than 65 C, but less than 100 C,
and most preferably at 75 C. They are preferably conducted
in saline solution (e.g., NaCl). Preferably, the bacteria
is subjected to this treatment for about 2 hours to ensure
that the objectives are accomplished.
The disclosed killing of the bacteria, e.g. by
heat treatment of the finally produced Kyberdrug according
-41-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
to Scheme I after washing off from the solid Endo-Agar or
Diagonal Agar, respectively, with isotonic NaCl solutions
ensures that no contamination of exogenic material
including those from extracellular-bound bacteriocin like
materials during harvesting with the Kyberdrug is
occurring. Since the bacteriocins like proteins which are
extracellular bound are unstable at temperatures above 55-
60 C, the heat treatment at higher temperatures ensures
that the final product is free of unwanted endogenic
organic material. This can be analyzed through very
sensitive HPLC (high performance liquid chromatography)
analysis using a sensitive UV-detection system, or in the
presence of a bound fluorescent indicator such as ethidium
bromide or fluorescein at an excitation wavelength of 295
nm and an emission wavelength of 367 nm, respectively.
This heat treatment affords a bacteria shell containing the
Kyberdrug.
Depending on the loading with bacteria on the
Diagonal Agar, viable bacteria can be isolated since they
are cultured on Petri dishes. However, i) these grown
microorganisms are not pathogens due to the selection
process as tested by the PCR method. Moreover, if the
suspension is subjected to conditions which kill the
bacteria, such as heating, e.g. up to 75 C, as described
hereinabove and, according to Scheme I, the replication is
completely lost, and only the Kyberdrug is left behind.
Furthermore, the Kyberdrug released can adopt in
the presence of 0.9% salt certain dynamic micellar forms,
which are pH, temperature and counterion dependent,
particularly Ca" and Mg". These conformational changes, or
physical morphology changes is driven by charge
interactions as observed by light scattering techniques
-42-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
(colloidal crystals) within the head groups of the
Kyberdrug molecules (monomer = micelle equilibrium). Very
similar interactions are occurring between the Kyberdrug
molecules from rough as well as smooth strains.
Without wishing to be bound, it is believed that
the low osmotic pressure brought about by the low saline
NaCl solution also increases the segregation of the
Kyberdrug from the shell. Optionally additional PCR'tests
can be performed to verify that the product obtained
contains the desired material and does not contain any
substances that is capable of being amplified. For
example, nucleic acids or oligonucleotides are not present,
or contaminating the Kyberdrug. Therefore the inactivation
step is not only an additional security step, it is an
important production step together with the Diagonal Agar.
This means that the bacterial "shell" is devoid of any
replicating material, because all other contaminants or
contaminant bacteria are eliminated. In addition there
should be no replicating machinery left, hence there is
also no debris from the proteins which are involved in
ribosomal biosynthesis.
Alternatively, instead of saline or phenol, the
selected strain may be rinsed with sodium EDTA, 0.0025%
(w/w) phenol, 0.005-0.015 %(w/w) ZnC12 , or with a solution
of 0.1 - 0.001% (w/w) ZnC12 -D-gluconate. The wash
contains all the specific medicinal activities associated
with the enhanced response towards foreign or hostile
bacteria, viruses or immune-modulating effects. By rinsing
the outer surface of the microbial shell, the
lipooligosaccharide is released, but it is strongly
influenced by the ionic strength of the saline solution and
temperature. The saline wash with low ionic strength at pH
-43-
CA 02436107 2009-07-31
between 4.5 - 7.0 is essential for the preparation of the
Kyberdrug._ Instead of saline, the "bacteria" may be
additionally washed with tris(hydroxymethyl
aminomethane=HC1. However, it is preferred that low
concentrations of tris(hydroxymethyl)aminomethan=HC1 (e.g.,
in the range 15 - 50 mm or less) are not utilized, if used,
it is preferred that it is present in concentrations of
at least about 100 mM (pH 7.0). Other amines, even at low
concentrations, may also be used as the rinsing agent.
Again, to ensure that the there is no endotoxin present,
the PCR reactive material test may optionally be performed
and if the results are positive, then the strain is
discarded; but if negative the procedure is continued.
However, the Kyberdrug thus obtained may be
extracted from the bacterial shell and then purified prior
to being made into a pharmaceutical formulation by
techniques known in the art. Two exemplary methods are
outlined in Scheme 2.
In one methodology, the Kyberdrug is extracted
with methanol/chloroform or methanol/acetonitrile. in this
method, CHC13 /CH3OH or CH3CN/CH3OH, preferably in a
concentration ranging from about 4:1 to 1:4 (v/v) and more
preferably about 1:1 (v/v) is used; the Kyberdrug is placed
therein preferably with stirring, and is heated to ref lux
under conditions sufficient to extract the Kyberdrug from
the bacterial shell. The Kyberdrug precipitates therefrom
and is collected. The crude Kyberdrug is then subjected to
chromatography, such as HPLC using silica or alumina or
methacrylate as the absorbent, or molecule exclusion
chromotography, using a SephadexTM column or DEAE cellulose
column or BioGel using such solvents as chloroform,
methanol, acetone, acetic acid, propionic acid, and the
-44-
CA 02436107 2009-07-31
like. In a preferred embodiment, the precipitate is
purified in preparative HPLC at room temperature wherein
the adsorbent is RP- 18, (methacrylate) SephadexTM, G- 100, G-
200, SepharoseTM 2B, DEAE SepharoseTM, G-75 medium and the like.
Preferably, a calibrated HPLC column using a spherical
matrix, e.g., methacrylate of mesh sizes of approximately
50 - 100 um and a light scattering detector attached to the
HPLC apparatus is used to validate the size and mass of the
Kyberdrug after calibration of the HPLC column with
standards. This permits the size and shape of the Kyberdrug
to be continuously monitored,. and allows the final product
to be validated throughout the production (in-process
control).
The HPLC is connected to a UV spectrophotomer and
the material which absorbs at 550 nm is collected. The
fractions are pooled and the product is lyopholized.
Alternatively, the bacterial shell is placed with
continuous stirring in a salt solution to form an aqueous
dispersion at 20 -30 C. The salt is present in low ionic
strength, e.g., less than 0.5 molar and more preferably
less then 0.2 molar, but greater than 0.05M. Most
preferably, the salt concentration is 0.154M. The
preferred salts are inorganic salts, such as KC1, and
especially NaCl and the like.' The aqueous dispersion is
stirred for sufficient time and under effective conditions
to remove substantially all of the Kyberdrug from the
bacterial shell. The aqueous dispersion is then passed
through a SephadexTM cdlumn, preferably SepharoseTM 2(3 or 6(3 as
matrix or BioGel at 25 C in the presence of a solvent, such
as mild saline solution (NaCl) having a pH between 6.5 and
7.5 at 20 C at an effective flow rate, such as, for
example, between 0.1 and 10 ml/min. The material absorbing
-45-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
at 230 nm and 550 nm is collected, the latter being the
adsorption in the W of the aggregate of the modified Lipid
A, while the former is the absorption of the monomer in the
W. The active fractions are pooled and then subjected to
lyophilization. The pooled lyophilized fractions are
dissolved in CHC13/MeOH or CH3CN/MeOH in a ratio ranging
from 6:1 to 1:1 (v/v), respectively and more preferably
from about 5:1 to about 3:1 (v/v), respectively and most
preferably at about 4:1, respectively and heated to reflux
for sufficient amount of time to separate out the
Kyberdrug, which is then chromatographically purified using
standard techniques known in the art. Preferably, it is
passed through a DEAE-cellulose chromatographic column at
25 C where the eluent is a mixture of acetonitrile and
methanol or CHC13/MeOH solution wherein the acetonitrile or
chloroform to methanol ratio ranges from about 6:1 to about
1:1 and more preferably from about 5:1 to about 3:1 (v/v)
and most preferably about 4:1 (v/v). Added thereto per
liter is a gradient of acetate or propionate salt ranging
from 0.00 to 0.75M concentration.
The phosphate content thereof is determined using
a phosphate ion detector. The phosphate detector may be
connected to the column. In any event, as the eluent
passes by the phosphate monitor, the phosphate
concentration is determined; those fractions which do not
contain any measurable phosphate content, or contains a
minimal amount of phosphate is collected. The UV of each
fraction is also measured at 550 and 230 nm. Again, it is
preferred that a W detector be attached to the column,
such that the eluent passes through a W detector. Only
.those fractions which exhibit absorptions in the UV at 550
nm and/or 230 nm are collected and pooled.
-46-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
The size variation of the Kyberdrugs, including
their mass distribution, and the validation of the monomer
state of the material, i.e. no temperature induced or salt
induced aggregation, can be monitored using either method
through Gel-permeation chromatography using Sepharose 2B or
6B as described before. The exclusion limits are 10 x 106
Da (Sepharose 2B) and the inclusion volume is assigned to
molecules smaller than 100,000 Da, respectively.
Simultaneous determination of the eluting material at 220,
265 and 280 nm in the absence of a fluorescent dye will
record the purity and homogeneous chemical composition
(absence of any contamination with nucleotides and nucleic
acids, respectively, and absorbing proteins) of the
Kyberdrug. The actual absorbance of the material on an
absolute scale can be monitored at 660 nm using a light
scattering detector with the appropriate cell by measuring
the changes of the refractive index increment, (dn/dc)T,p
.The results obtained are consistent with those derived
from static light scattering experiments, transmission
electronmicroscopy and HPLC runs as described above. A
preferable eluting system for determination and validation
of the size and concentration of the Kyberdrug utilizes an
isocratic gradient and a Microsphere column (Beckman, USA),
in which the Kyberdrugs are dispersed in an aqueous solvent
containing 0.10 -0.190 M NaCl. The refractive index of
Kyberdrug samples, (dn/dc),,T, where ii is the chemical
potential and T the absolute temperature, was determined to
be about 0.160 0.0005 mL/g, after calibration of the
refractive index increments applying inter-ferometric
methods as described in H.H.Paradies et al.,
J.Phys.Chem.,100, 9881-9891, 1996 and H.H.Paradies,
-47-
CA 02436107 2009-07-31
J.biol.Chem., 254,7495-7505,1979.
By following either of these two techniques, a
substantially purified Kyberdrug is obtained. Preferably,
it is greater than about 70% pure and more preferably
greater than about 85% pure and most preferably at least
90% pure.
Using the procedure described herein permits the
selection only of those strains which are'devoid of these
pathogenic factors as stated before. Applying
amplification methods according to the procedures known in
the art permits the isolation of the appropriate strain,
ensures the separation of the suitable strain of
microorganism from the toxic one and provides the final.
product, i.e., the Kyberdrug, which is devoid of any lethal
or pathological factors.
This selective process for obtaining the
microorganisms before culturing at large is an essential
part of the success of obtaining the desired material since
it discloses the absence of any toxic or other pathological
contamination of the Kyberdrug used for further culturing
and harvesting, respectively. Particularly, the selection
of said microorganisms from those containing the typical
features of pathological appearances makes this process
very special and attractive for analytical reasons as well
as safe with regard to elimination of pathologic bacterial
strains, viral or bacteriophage-like material (PCR-method)
for further processing on an industrial scale.
-48-
CA 02436107 2009-07-31
Physical-Chemical. Analysis and Stability of Kyyberdru
Analyses of samples obtained according to this
disclosure have been performed by means of static and
inelastic light scattering experiments including diffuse
wave spectroscopy in order to deduce size and shape of the
material in the absence of salt and in the presence of salt
solutions. The techniques utilized are described by
Paradies, Colloids & Surfaces, 74, 57-69, 1993.
The
inventors have found that the samples of Kyberdrug contain
a constant diameter of 0.65 pm at a constant chemical
potential with a fairly small dispersion (5) of 10-15%
only. The size variation (5) of the Kyberdrug at ionic
strength of 0.153 M NaCl at constant pH (6.9) and
temperature did not change significantly when the ionic
strength was raised to 0.350 M NaCl. However, a shrinkage.
of the hydrodynamic radius was noticed when measured
through inelastic light scattering experiments and obtained
from the autocorrelation function of the decay spectra, in
which a change from an average of 0.65 pm at 0.153 M NaCl
(20 C) to 0.57 0.06 pm at 0.350 M NaCl (20 C) was found,
which is reversible upon changing the salt concentration
back to the initial concentration. Moreover, below 0.153 M
NaCl (20 C) the Kyberdrug expanded to an average 0.70
0.08 p m at 0.015 M NaCl which is reversible, too.
The Kyberdrug obtained is a colloidal solid,
which exists in crystalline form.
The Kyberdrug of the.present invention are
stable.
without wishing to be bound, it is believed that
the colloidal stability of the Kyberdrug can be understood
in terms of the DLVO theory (see e.g. E.J.Verwey,
-49-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
J.Th.Overbeek: Theory of the Stability of Hydrophobic
Colloids; Elsevier, Amsterdam 1948) which takes into
account the electrostatic and the Lifshitz-van der Waals
electrodynamic interactions between particles of certain
sizes. The colloidal stability of the Kyberdrug and of
E.Coli, respectively, which both carry negative charges at
their external surface areas, as determined from
electrophoretic light scattering and particle
electrophoresis, are then interpreted in terms of the
nature of the energy distance curves. For two spheres e.g.,
A and B, where A can be equal to B or different from B, and
taking the determined average values for the Kyberdrug into
account (0.65 pm), the mode of dependency of the A-B
interaction on the separation distance can be calculated.
Surprisingly, for the Kyberdrug, the values are positive,
whereas those for E.Coli are all negative at all distances.
When the A-B interactions are predominant over the
electrostatic and van der Waals interactions, E.Coli
(replicating state) has to flocculate rapidly (which is
actually the case), while the Kyberdrug, indeed due to
their repulsive A-B interactions, will remain dispersed at
constant chemical potential, e.g. ionic strength and
constant temperature. Unlike typical double-layer
interactions, the A-B interaction potentials are largely
insensitive to variation in electrolyte concentration and
pH, as noticed for the Kyberdrug; hence their narrow size
distribution and insensitivity to small changes in ionic
strength finds its explanation here. The Kyberdrug remains
stable for a period of time of several weeks. This
situation does not change upon the presence of 0.25% (g/g)
phenol. The colloidal stability of the Kyberdrug is further
demonstrated by measuring the changes of the degree of
-50-
CA 02436107 2009-07-31
hydration by means of NMR techniques, as well as of the
actual mass using a ng-balance (quartz) for a certain
number density of Kyberdrug. These measurements on samples
obtained in accordance with the procedure described
hereinabove revealed a mass density of an average of (1.51
0.0095) x 10-9 g/mL, a degree of hydration of an average
of 0.15 x 10-4 g/g (g water/g Kyberdrug) , which is
approximately 30% of the total mass of the material in the
presence of 0.153 M NaCl. The translational diffusion
coefficient and its dispersion under these conditions, as
determined from the autocorrelation function, obtained
through inelastic light scattering experiments (the method
and the setup is disclosed by Paradies et al. in
LT.Phys.Chem. 98, 11143-11162, 1994, or ibid., 100, 9881-
9891, 1996,
yielded values of D = 0.432 pmt/s and a
particle density of <q> = 2.18 x 1018 M-3 with a surface
potential of 0.17 0.02 V. Furthermore, the observation of
opal formation of the Kyberdrug arising from the weak
interaction of pm particles can be documented also through
transmission electron microscopy (TEM, 2,000 keV) with a
1.7 nm point to point resolution (Fig.1). This finding
with respect to the colloidal stability demonstrates that
the observed "configuration" of the Kyberdrug corresponds
to the minimization of the mesoscopic van der Waals energy
of polydisperse particles. However, the driving force is
the size dependence of the dispersion attractions. In
addition there are surprisingly three important features to
note: The radial distribution of particles sizes within the
"island" is highly ordered, with the largest particles
(approximately 0.6_- 0.65 pm) positioned at the center, and
the smallest particles at the extreme borders. Secondly,
-51-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
the separation between nearest neighbors is independent of
the particular Kyberdrug core sizes involved. Finally,
even though the large particles constitute only = 3% of the
total size distribution, they are able to nucleate and
drive the. formation of this opal Kyberdrug in the presence
of 0.153 M NaCl. The results obtained are consistent with
static light scattering measurements revealing a
hydrodynamic radius of about 0.56 pm and a shape which is
close to a hollow spherical particle with a thick outer
shell that is highly negatively charged and pH dependent as
well as salt dependent.
Light scattering curves can be obtained from
colloidal crystals of Kyberdrug at low volume fractions in
the presence of 0.154 M NaCl (25 C). (See, e.g., Fig. 6).
The results can be compared to light scattering curves
obtained from colloidal crystals of Kyberdrug under the
same conditions at 37 C, which is about the melting point
of the Kyberdrug (Fig. 7). These results combined together
with the results obtained from inelastic light scattering
experiments, and diffusive wave spectroscopy, performed
simultaneously on the same material under identical
conditions support the conclusions that this material
(Kyberdrugs) is composed of many colloidal crystals which
are stabilized and separated from each other through strong
electrostic forces and hydrodynamic interactions. This
conclusion is further supported from the'X-ray diffraction
pattern at 25 C (Fig. 8A) as compared to the X-ray
diffraction pattern at 37 C (Fig. 8B).
The dynamic light scattering measurements and the
static light scattering measurements were performed on a
ALV light scattering goniometer 5000 (Langen, FRG). The
goniometer spans from 15 to 250 in the scattering angle
-52-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
(0) and a He-Ne-laser (10 mW) was used as a light source at
633 nm. The source of light was vertically polarized after
passage through two pinpoint holes, and the focuses on the
center of the cell. The measurements reveal that the
suspensions of the Kyberdrug are crystal.-like and
structures of the Kyberdrug are fcc or face closed packed
and/or bcc. Moreover, it was noted that the crystal
lattice of the Kyberdrug can be transformed from a fcc
subphase to the bcc phase under certain conditions. More
specifically, it was noted that the bcc lattice
transformation is high i.) when the salt concentration is
lowered to less than about 0.1 M and more preferably less
than 0.07 M NaCl, ii.) the suspension temperature is
lowered below about 50 C and more preferably to about 37 C
(- 20-25 C), iii.) the charge density of the spheres is low
due to the configuration charge rather than the unit charge
of the polyelectrolyte (see above), or iv.) the osmotic
pressure is low and time has elapsed since the preparation
of the suspension containing the Kyberdrug or the technique
of the preparation of the Kyberdrug in the presence of salt
or pH is not changing during the formation of the colloidal
crystals.
The Kyberdrugs do not self-aggregate under
physiological and/or pharmaceutical conditions. At low
ionic strength (1 mM NaCl and lower, e.g. 0.05 mM NaCl),
the size distribution increases only slightly due to
hydration, but the initial mass of the Kyberdrug does not
change significantly. Increasing the ionic strength (250 mM
NaCl) does not change the actual mass of the Kyberdrug that
is being detected; it only decreases the hydration-of 10-
15% as determined by NMR measurements.
-53-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
This behavior has also been observed from
measurements of the viscosity of the Kyberdrug suspension
under different ionic conditions at constant temperature,
confirming that there is no large changes with dilution,
thereby supporting the virtual non-existence of'large
electrostatic interactions without conformational change
This means that the interactions are not directly related
to the Debye length.
The Kyberdrug produced in accordance with the
present invention are useful therapeutics. For example,
they are useful in treating various diseases, including
cough and colds, mainly caused by rhinoviruses and
influenza viruses, catarrhal inflammations, skin infectious
and infective dermatoses; dermatomycose, bacterially
induced skin lesions, such as pyroderma, acne in patients
suffering from inflammatory forms with pipules and
pustules, acne vulgaris; otitis media, microbial and
secondary infected exzema; mycoses, bacterial infections
and secondary infectious to the skin due to gram-positive
and or gram-negative.bacterial.infections, sinusitis,
candida infections, particularly against candidaces of the
skin, nails and mucus membrance, squamous cell carcinoma of
the skin and mucosa, acute and chronic rheumatism and
dermatological malignant growth. It also is useful in
preventing viral infection and bacterially induced lesions
such as pyoderma, and it represses carcinogen induced (line
10) hepatatocellular carcinoma.
It is believed, without wishing to be bound, that
the ability of the Kyberdrug to induce a series of
different antibodies in the early stimulating event of
cellular and humoral immunity in a specific array makes it
possible and applicable to protect the human (mammalian)
-54-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
organism against foreign invaders. Particularly, the
Kyberdrug are capable of stimulating those cells which
produce antigens and can increase these specific antigens
in order to delete the invaded hostile microorganism, or
chronic inflammation. The fast selection is brought about
by the stimulated B-cells in order to generate specific
antibodies.
It also reduces the side effects of asthma
attacks. Without wishing to be bound, it is believed that
it inhibits the key allergic factor, the atopy. Responding
in an unique way to the Kyberdrug, the atopy response is
reduced through the interaction of the antigen with the
Kyberdrug, e.g., thereby reducing swelling from the influx
of water and immune cells into tissue, local blood-blood
vessel deletion and smooth muscle spasm.
The Kyberdrug of the present invention, as shown
hereinbelow, influences the production of the cytokines and
interferons.
It has antibacterial and anti-viral activity.
Kyberdrugs confer humoral and intestinal
immunity.
Kyberdrugs may also be incorporated into regular
and clinical immunization, also with other injectable
vaccines, e.g. diphtheria, pertussis, tetanus;
Kyberdrugs are non-replicating agents; they
exclude the potential for mutation and reverse virulence as
well as bacterial infections; the absence. of replicating
virus and/or bacteria of the Kyberdrug permits its use in
immunodeficient or immune-suppressed individuals and their
hosts;
Kyberdrugs possess antiviral activities due to
its polyvalent character; they inhibit viral replications
-55-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
of Herpes simplex, yellow fever, and polio viruses, without
having any significant anticoagulant activity;
Kyberdrugs stabilize mast cells and prevent mast
cells from secreting from their own internal granules such
mediators of inflammation as histamine and leukotrienes
when allergens bind to IgE molecules on mast cell surfaces.
Therefore the Kyberdrug is useful for treating chronic
inflammatory rheumatic diseases, particularly for chronic
rheumatory diseases; e.g. osteoarthritis, muscle arthritis
and primary chronic arthritis.
it is believed, without wishing to be bound that
the ability of the Kyberdrug to induce a 'series of
different antibodies in the early stimulating event of
cellular and humoral immunity in a specific array makes it
possible and applicable to protect the human (mammalian)
organism against foreign invaders. Particularly, the
Kyberdrugs are capable of stimulating those cells which
produce antigens and can increase these specific antigens
in order to delete the invaded hostile microorganism or
chronic inflammation. The fast selection is brought about
by the stimulated B-cells in order to generate specific
antibodies.
The Kyberdrugs are useful in treating bacterial
or viral infections and chronic as well as allergic
reactions. The Kyberdrug inhibits bacterial and viral
activities. They are useful in treating allergic diseases
including asthma and in treating diseases caused by DNA or
RNA viruses, including HIV viruses, and coated viruses.
Without wishing to be bound, it is believed that they
inhibit the rate of transcriptions of the reverse
transcriptase of retroviruses.
-56-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
The Kyberdrug is effective in treating bacteria
and viral infections in mammals. Patients treated with the
Kyberdrug exhibit a decrease in the magnitude of the
allergy or asthma attack as well as the frequency of the
symptoms, including the frequency of seizures. The effect
has also been observed in patients suffering from the
.rheumatic diseases.
Moreover, due to their small particle size and
colloidal crystals dispersed in diluted saline solutions
e.g. at concentrations ranging from about 0.05 to about 1M
NacL, and more preferably from about 0.1 to about 0.5M and
most preferably at about 0.1M to about 0.2M, the Kyberdrug
can be used as a vaccine against viruses and bacteria, e.g.
against Hepatitis B surface antigen. Moreover, the
Kyberdrugs can be used as an adjuvant against Type I
hypersensitivity to allergens, e.g. pollen allergens,
insect saliva allergens, insect part allergens, food
allergens and the like.
The present inventors have found that its
biological activity and its efficacy as a drug is enhanced
when administered with a calcium salt, even at
concentrations as low as 5-10nM calcium.
The Kyberdrug is administered in therapeutically
effective amounts. The Kyberdrug is quite efficacious;
only minute amounts need to be administered.
It is preferred that the Kyberdrugs of the
present invention be administered in amounts ranging from
about 0.01 mg to about 2 mg per kilogram of body weight per
day. This dosage regimen may be adjusted by the physician
to provide the optimum therapeutic response. For example,
several divided doses may be administered daily or the dose
may be proportionally reduced as indicated by the
-57-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
exigencies of the therapeutic situation. A decided
practical advantage is that the Kyberdrug of the present
invention may be administered in a convenient manner, such
as by oral, intravenous, intramuscular or subcutaneous
routes.
The Kyberdrug prepared from individual patients
can be administered to these individuals again without
showing any allergic reactions nor anaphylactic shock
symptoms.
Moreover, the Kyberdrug is non-toxic. Without
wishing to be bound, it is believed that the non-toxicity
results from the absence of any endotoxin activity as well
as to its efficacy, since only small doses are applied.
The Kyberdrugs of the present invention may be
orally administered, for example, with an inert diluent or
with an assimilable edible carrier, or it may be enclosed
in hard or soft shell gelatin capsules, or it may be
compressed into tablets, or it may be incorporated directly
into the food of the diet. For oral. therapeutic
administration, the Kyberdrug may be incorporated with
excipients and used in the form of ingestible tablets,
buccal tablets, troches, capsules, elixirs, suspensions,
syrups, wafers, and the like. Such compositions and
preparations preferably contain Kyberdrugs or
concentrations ranging from about 0.1% to about 99% by
weight. The amount of Kyberdrug in such therapeutically
useful compositions is such that a suitable dosage will be
obtained. Preferred compositions or preparations according
to the present invention are prepared so that an oral
dosage unit form contains between about 50 mg and 2000 mg
of active compound.
-58-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
The tablets, troches, pills, capsules and, the
like may also contain the following: A binder such as gum
tragacanth, acacia, corn starch or gelatin; excipients such
as dicalcium phosphate; a disintegrating agent such as corn
starch, potato starch, alginic acid and the like; a
lubricant such as magnesium stearate; and a sweetening
agent such as sucrose, lactose or saccharin may be added or
a flavoring agent such as peppermint, oil of wintergreen,
or cherry flavoring. When the dosage unit form is a
capsule, it may contain, in addition to materials of the
above type, a liquid carrier. Various other materials may
be present as coatings or to otherwise modify the physical
form of the dosage unit. For instance, tablets, pills, or
capsules may be coated with shellac, sugar or both. A
syrup or elixir may contain the Kyberdrug, sucrose as a
sweetening agent, methyl and propylparabens as
preservatives, a dye and flavoring such as cherry or orange
flavor. Of course, any material used in preparing any
dosage unit form should be pharmaceutically pure and
substantially non-toxic in the amounts employed. In
addition, the Kyberdrug may be incorporated into sustained-
release preparations and formulations. For example,
sustained release dosage forms are contemplated wherein the
Kyberdrug is bound to an ion exchange resin which,
optionally, can be coated with a diffusion barrier coating
to modify the release properties of the resin.
The Kyberdrug may also be administered
parenterally or intraperitoneally. Dispersions can also be
prepared. in glycerol, liquid polyethylene glycols, and
mixtures thereof and in oils.
The pharmaceutical forms suitable for injectable
use include sterile aqueous solutions (where water soluble)
-59-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
or dispersions and sterile powders for the extemporaneous
preparation of sterile injectable solutions or dispersions.
In all cases the form must be sterile and must be fluid to
the extent that easy syringability exists. It must be
stable under the conditions of manufacture and storage and
must be preserved against the contaminating action of
microorganisms such as bacteria and fungi. The carrier can
be a solvent or dispersion medium containing, for example,
water, ethanol, polyol (for example, glycerol, propylene
glycol, and liquid polyethylene glycol, and the like),
suitable mixtures thereof, and vegetable oils. The proper
fluidity can be maintained, for example, by the use of a
coating such as lecithin, by the maintenance of the
required particle size in the case of dispersions and by
the use of'surfactants. The prevention of the action of
microorganisms can be brought about by. various
antibacterial and antifungal agents, for example, parabens,
chlorobutanol, phenol, sorbic acid, thimerosal, and the
like. In many cases, it will be preferable to include
isotonic agents, for example, sugars or sodium chloride.
Prolonged absorption of the injectable compositions can be
brought about by the use in the compositions of agents
delaying absorption, for example, aluminum monostearate and
gelatin.
Sterile injectable solutions are prepared by
incorporating the Kyberdrug in the required amount in the
appropriate solvent with various of the other ingredients
enumerated above, as required, followed by filtered
sterilization. Generally, dispersions are prepared by
incorporating the various sterilized active ingredient into
a sterile vehicle which contains the basic dispersion
medium and the required other ingredients from those
-60-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
enumerated above. In the case of sterile powders for the
preparation of sterile injectable solutions, the preferred
methods of preparation are vacuum drying and the freeze-
drying technique which yield a powder of the active
ingredient plus any additional desired ingredient from
previously sterile-filtered solution thereof.
As used herein, "pharmaceutically acceptable
carrier" means a medium which does not interfere with the
medicinal activity of the active ingredient and is not
toxic to the patient to whom it is administered. Examples
include any and all solvents, dispersion media, coatings,
antibacterial and antifungal agents, isotonic and
absorption delaying agents, oil-in-water or water-in-oil
emulsions, aqueous compositions, liposomes, microbeeds,
microsomes, aluminum hydroxide (aluminum hydroxide salt)
and the like. The use of such media and agents for
pharmaceutical active substances is well known in the art.
Except insofar as any conventional media or agent is
incompatible with the active ingredient, its use in the
therapeutic compositions is contemplated. Supplementary
active ingredients can also be incorporated into the
compositions.
It is especially advantageous to formulate
parenteral compositions in dosage unit form for ease of
administration and uniformity of dosage. Dosage unit form
as used herein refers to physically discrete units suited
as unitary dosages for the mammalian subjects to be
treated; each unit containing a predetermined quantity of
active material calculated to produce the desired
therapeutic effect in association with the required
pharmaceutical carrier.
-61-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
The Kyberdrug may be compounded for convenient
and effective administration in effective amounts with a
suitable pharmaceutically acceptable carrier in dosage unit
form as hereinbefore described. A unit dosage form can,,
for example, contain the Kyberdrug in amounts ranging from
about 50 mg to about 2000 mg. In the case of compositions
containing supplementary active ingredients, the dosages
are determined by reference to the usual dose and manner of
administration of the ingredients.
The Kyberdrug may be administered in an aerosol
spray using techniques known to the skilled artisan.
It is preferred that the Kyberdrug is
administered in a subcutaneous form in the presence of
0.25% (w/w) phenol, or as a suspension of the desired
concentration of Kyberdrug in 1% NaCl, or as a saline
formulation in the presence 0.05%(w/w) ZnC12 having the
same iso-osmotic pressure as a 1% NaCl solution. Another
formulation comprises of 0.05-0.5 (w/w) Zn-D-gluconate or
gluconic acid phosphate, and the desired concentration of
Kyberdrug, in the presence of physiological concentrations
of NaCl.
Apart from these formulations, another form
consists of inclusion of the Kyberdrug in "carbomers",
named for various Carbopol homopolymer resins according to
the USP-NF, British Pharmacopoeia, United States Adopted
Names Council (USAN) and the Deutsches Arzneibuch, which
calls e.g. Carbopol 980 NF "polyacrylic acids". Carbopol
resins, e.g. Permulen as a polymeric emulsifier and Noveon
as polycarbophils, are polymers of acrylic acid crosslinked
with polyalkenyl ethers or divinyl glycols. The powdered
materials are supplied as flocculated materials (powders)
of primary particle size averaging about 0.15 pm in
-62-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
diameter. The flocculated powders average 2 to 7 um in
diameter as determined by inelastic light scattering
measurements, consistent with the measurements of the
supplier, BF. Goodrich Specialty Chemicals, Cleveland,
Ohio, 44141-3247, USA.
Since bioadhesion, particularly mucoadhesion, is
desired for the mode of action of the Kyberdrug, the
pharmaceutical inactive material must interact with mucus,
which is a highly-hydrated, viscous anionic hydrogel layer
protecting the gastric mucosa. The Kyberdrug is dispersed
in bioadhesive material such as polyacrylic acid polymers,
e.g. Carbopol , or Novean AA-1 USP polycarbophil resins and
Permulen polymeric emulsifiers, which make excellent
bioadhesives for the encapsulated Kyberdrug. The
polyacrylic acid polymers are preferred due to the
advantage of the swelling and adhesion properties of these
high-molecular weight polymers, and they are especially
very suitable for inclusion of the Kyberdrug. Furthermore,
the additional large adhesive surface area of these resins,
in addition to the large surface area of the Kyberdrug,
makes it very suitable for maximum contact with the gastric
mucus or intestinal mucus layer.
A preferred formulation uses the Kyberdrug in
combination with polyacrylic acid based material, such as
Noveon AA-1 USP or Carbopol 943P. These polymers, as
produced, are flocculated powders having particle sizes on
the average of 0.2 um in diameter. Since the Carbopol
resins as well as the Noveon polycarbophils are high
molecular weight polymers of acrylic acid, which are
chemically crosslinked with polyalkenyl alcohols, the
crosslinked materials are water insoluble, but swellable in
water or saline solutions.
-63-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
Preferably a polyacrylic acid gel of 1.0-1.79
(w/w) and preferably between 0.7-0.8% (w/w) solids are
used, dispersed in deionized water and neutralized to a pH
of 4.5-5.0 at 25 C. To the polyacrylic gel is added the
desired amount of Kyberdrug material in a saline solution,
which is preferably less than about 1M saline solution and
more preferably less than about 0.5 saline solution and
even more preferably less than about 0.2M saline solution.
It is most preferred that the Kyberdrug is dissolved in
about a 0.154 M saline solution. Alternatively, the
Kyberdrug is deionized and lyophilized, and finally
dispersed, under continuos stirring, with the acrylic based
materials in the presence of water or any desired solutions
if the Kyberdrug are administered as a solution, and then
sterilized. Whichever methodology is used, it is preferred
that the pH of the Kyberdrug solution ranges between about
3.5 to 6.5 and more preferably between 4 and 5 and most
preferably the pH is about 4.5 0.2 (25 C).
Another pharmaceutical formulation comprises the
desired amount of Kyberdrug in an aqueous solution of
dilute, i.e., less than 5% and more preferably less than 3%
and most preferably about 1% (w/w), human or bovine serum
albumin at pH 4.5-5.5. This is prepared readily from a 40%
(w/w) stock solution by dilution with the saline solution.
Another pharmaceutical formulation comprises the
desired amount of Kyberdrug in association with a hydrogel
or polymers of acrylic acid, such as Noveon A-2-USP,
Noveon AA-USP polymers or Cabopol 934 PNF. These
polymers form a gel when exposed to a pH environment
greater than 6.5 0.5, i.e., in acid pH. Upon swelling,
the Kyberdrugs are released especially when the Ca 2 salt of
polycarbophils (Noveon ) is applied.
-64-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
The hydrogel formulations containing the desired
amount of Kyberdrug are discrete microgels comprised of
many polymer particles in which the Kyberdrugs are
dispersed. Although the hydrogels are not water soluble,
when fully hydrated, osmotic pressure from within forms
holes in structure, permitting the Kyberdrug to diffuse
through the gel layer.
The hydrogel formulations described hereinabove
containing Kyberdrug are also useful for phonophoresis.
The Kyberdrug is in the form of a gel and is applied
directly to the skin at the infected area. Frequencies in
the range of 11-15 MHz are applied thereto; this action
helps to diffuse the high molecular weight material
(Kyberdrug) through the skin. Furthermore, in this special
formulation, low-frequency ultrasound just above the range
that is audible to the human ear enables dissolved
Kyberdrug in carbophils in lipid regions between skin cells
to penetrate and start to move into the interior.
Furthermore, the system described hereinbelow in
association with the polymers of acrylic acid can be made
into an adhesive-backed tablet using techniques known in
the art. The tablet is placed between the gum and the lip.
As the tablet with the Kyberdrug dissolves, it delivers the
Kyberdrug directly into the bloodstream via the mucous
membrane of the mouth. The tablets, containing the
Kyberdrug, according to the disclosed formulation, can be
less than 1 cm in diameter. The tablet comprises the
carbophil-permeation-enhanced oral transmucosal system
described above. Additionally, they may contain an
enhancer, such as alginate as the Ca-salt or highly
pyruvylated Xanthan, respectively.
-65-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
Another preferable pharmaceutical formulation for
the Kyberdrug comprises complexes between Kyberdrug and
enantiomers or racemates of lysine, ornithine, arginine and
methionine. Another embodiment for solid and liquid
formulations, especially for administration parenterally,
consists of the Kyberdrug in association with 1-amino-1-
deoxy-D-glucitol (glucamine), or ribamine (which is the
galactose stereoisomer), D-gluconic acid or its 5-lactone.
Another preferable formulation comprises the Ca2+,
Mg 2+ and Zn2+- salts of the gluconic acid or its
corresponding 6-lactone in association with Kyberdrug. The
Zn2+ salt of D-gluconic acid, Zn [OOC- (CHOH) 4-CH2OH] 2 or the
corresponding Ca2+ or Mg2+ salts are very water-soluble
having optical rotations of [a] D -6 .7 (c=l), [a] D -5.9
(c=0.75), and [a] D-9.5 (c=1), respectively, at pHs. between
4.7-5.5 (20 C) in the presence of Kyberdrug. This complex
between the Kyberdrug and the metal-gluconic acid compounds
when placed in aqueous solution forms a clear and
transparent solution and can be formulated into a large
range of concentrations of the Kyberdrug, e.g. 1.0 to 10
mg. In addition, these solutions have a very low surface
tension of about 32 mN/m in the presence of 1.0 x 10-5 g/mL
Kyberdrug, versus 79 mN/m just for the D-gluconic acid salt
complexes alone. Moreover, when the material is
lyophilized, the re-dissolved powder in water or saline
solution yields a transparent solution again, revealing
after analysis no deterioration of the Kyberdrug or loss of
biological activity, respectively.
Simple formulations for the Kyberdrug make use of
the binding capacity of this material with Ca2+, Mg2+ and
Zn2+ ions at concentration of about 0.001% by weight to
about 0.1% by weight and most preferably about 0.01% (w/w)
-66-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
Zn2+ (e.g. as a chloride), 0.001% by weight to about 0.1%
(w/w) and most preferably about 0.002% (w/w) Ca'*' or 0.01%
(w/w) to about 0.1% (w/w) and most preferably 0.04% (w/w)
Mgt+(preferably as chlorides or hydroxides). These
solutions can be prepared also in the presence of 1% (w/w)
NaCl solutions without changing the osmolarity of the total
solutions. These formulations have the advantage of not
having phenol in the formulation, but showing the same
stability (e.g. shelf life time, storage) and antimicrobial
activities as solutions containing 0.25% (w/w) phenol when
administrating the Kyberdrug subcutaneously:
Delivery of Kyberdrug in the presence of liposome- like
formulations.
The Kyberdrug can also be formulated with
cationic lipids or derivatives thereof, e.g., dipalmityl-.,
or dipalmitoylphosphatidylcholine, dipalmityl-dimethyl
ammonium chloride or racemic or enantiomeric lactate, as
well as the corresponding C18-di n-alkyl dimethylammonium
derivatives in a pharmaceutical formulation. More
specifically, they can be applied as an aerosol, which'
contains the Kyberdrug in a liposome. Thus, the Kyberdrug
can be administered to the lung non-invasively.
Either dipalmitoylphosphatidylcholine (e.g., 1%
w/w) which is a zwitterionic lipid that can act as a weak
cation at physiological pH, dispersed in NaCl solution
(e.g. oilsum), or dipalmitoylphosphatidylcholine
(preferably 1:1 as a 1% w/w solution) in the presence of
the wanted Kyberdrug concentration can be used, and the
liposome-like dispersions easily prepared by sonication
using standard equipment (50 W, 35 C, 1.5 min.).
Microemulsions can be prepared by using the same cationic
-67-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
lipid materials; additionally, the carrier may be medium
olive oil, or oleyl alcohol [(Z)-9-octadecen-l-ol] or oleic
acid [(Z)-9-octadecenoic acid] as well as the corresponding
sodium salts of oleic acid in the presence of 10% (w/w)
water. Also a preferable preparation is the liposome-like
formulation of dipalmityl- or dipalmitoyl-dimethylammonium
lactate or S-enantiomer) or pyruvate as counterions in a
solution with dioleyl phosphatidylamine (1:lw/w) in 0.154 M
NaCl. The Kyberdrug is encapsulated in these lipids
through spiking of the Kyberdrug with ethidium bromide or
covalently fluorescent labeling Kyberdrug, i.e, with
fluorescein thiocynate or dansyl chloride.
Aerosols containing Kyberdrugs can be generated
by an ultrasonic nebulizer, e.g., Model 646. DeVilbiliss,
Sumerset, PA, which produces aerosol droplets of
approximately 5 um in diameter.
Unless indicated to the contrary, percentages are
by weight.
Moreover, the singular include the plural and
vise versa.
The term Kyberdrug includes not only the material
isolated from the bacterial shell but also the product that
is obtained after completion of the isolation steps
described in Scheme 1. As used herein, the term Kyberdrug
consists of the aggregate of monomer units. When referring
to the monomer, the term monomer or modified lipid A
molecule is utilized interchangeably.
The term "mammal" includes any species of the
class mammalia and includes without limitation cat, dog,
horse, goat, pig, and human. The preferred mammal is a
human.
-68-
CA 02436107 2003-04-04
WO 02/28424 PCT/IB01/02284
The following non-limiting examples further
illustrate the present invention.
-69-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 1
Upstream processing & downstream processing of
Kyberdrug.
Non-pathogenic E.coli cells obtained from
specimens of patients were grown on one of the media listed
in Tables I & II after having met the selective criteria
according to Table III in a Btichi Reactor-1.5 liter
fermenter (Biichi Glas Muster, 1991, Fab.# 111 010,936,1385)
at 37 C for 12-14 hrs. The cells were harvested by low
speed centrifugation (3,000 rpm at 37 C), washed several
times with deionized water (37 C), and either stored for
further processing in water at 5 C as a sediment, or freeze
dried and stored over Silica Gel at 5 C. The Kyberdrug was
detached form the cells either by i.) 0.154 M NaCl at 20
C, by continuously rinsing the cells with an 100 fold
excess of salt solution (0.154 M NaCl), or in the presence
of 0.01 %(w/w) ZnC12-gluconate; or ii.) by 11.5% (w/w)
phenol/chloroform extraction, subsequently followed by
88.5% chloroform extraction, and adding six volumes of
ether/acetone (1:6 v/v) in the presence or absence of ZnCl2,
or ZnC12-gluconate or ZnCl2- gluconic acid phosphate,
respectively; or iii.) by rinsing with 0.025% (w/w) phenol
in the presence of 0.154 M NaCl. The resulting precipitate
was collected and filtered, subsequently lyophilized, and
stored over Silica Gel at 20 C. The yield was 4.8 g of
crude material (Kyberdrug) per 150 g dry E. coli cells.
500 mg of the crude material was dissolved in 50
mL acetonitrile-methanol (5:1,v/v). The resulting slightly
opal solution was subjected to heating at a temperature
ranging from 50-60 C for 60 min. The resulting product was
then centrifuged again at 20,000 rpm (Beckman Centrifuge,
J2-21 Rotor) at 20 C. A clear and transparent solution was
-70-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
obtained. This prepared material was subjected to Sepharose
2B (Pharmacia) column chromatography (1.5x150 cm) at 20 C.
The column had been previously equilibrated by using the
acetonitrile-methanol co-solvent (5:1 v/v) as described
above. After loading (normally 50 mg) with the crude
Kyberdrug, the column was eluted with a different.
concentration of acetonitrile-methanol solution (3:1, v/v,
20 C). Fractions of 1.5 mL were collected, analyzed for
phosphorous content applying standard methods, and active
fractions were collected, pooled and subsequently freeze
dried. About 50 mg crude Kyberdrug, was obtained. This
material was then subjected to the selective criteria
outlined in Table III, or the screening process according
to Scheme I to avoid any contamination with LPS-like
material, lipid A, or other cell debris, which could
contaminate the pooled fractions.
Fractions obtained by Sepharose 2B column
chromatography were also analyzed by thin layer
chromatography using inactivated. Silica Gel H plates (Merck
Darmstadt, FRG). 1.5 mg of Kyberdrug were loaded onto the
plate (500 pm x 20 cm). The solvent system was
acetonitrile-methanol-water-conc. NH3-water in a ratio of
80:10:5:2 (v/v) at 30 C. The bands of Kyberdrug were
visualized by spraying with either iodine,or alkaline Cu-
tartrate solutions. Alternatively, 0.001 M NaOH may be
used instead of conc.NH3-water in the ratios indicated
hereinabove in combination with ninhydrin (spray). Other
purification steps for low concentrations of Kyberdrug (100
pg scale or less) include high liquid performance
chromatography (Scheme II) using a 100 RP-18 column
(LiChrosphor, Merck, Darmstadt, FRG), and applying an
isocratic gradient ranging from 80% (v/v) of acetonitrile
-71-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
and 20% (v/v) methanol to 95 % (v/v) acetonitrile
containing 5%(v/v) methanol. The resolution of the
Kyberdrug on the column was monitored either by 220 nm, or
by measuring the changes of the refractive index increment,
(dn/dc)u,T with retention time at 550 nm by light scattering
detector techniques routinely, or by determinations of the
phosphate content applying a phosphate sensitive electrode.
In this case the samples have to be either hydrolyzed (10
ug/1mL) routinely, or after calibration of the phosphate
sensitive electrode with a Kyberdrug standard directly.
-72-
CA 02436107 2009-07-31
EXAMPLE 2
1 mg of pure Kyberdrug was dissolved in 10 mL of
methanol (25 C) and diluted with aqueous solutions of 0.154
M NaCl (25 C), yielding the concentrations of Kyberdrug of
500 U.g/mL down to 10 .0 pg/mL. The final concentration of
Kyberdrug is determined by dry weight measurements, or by
determination of the scattering at 550 nm using a standard
for calibration, or by determining the phosphate content
e.g. according to Bartlett, J. Biol.Chem., 234, 466-471,
(1959).
0.52 jig phosphate/mg Kyberdrug equals 0.48 dig/mg
glucosamine-a typical constituent of the Kyberdrug-
resulting in a constant ratio of glucosamine to phosphate
of 1.08 0.04 for the monomeric form of the Kyberdrug. The
weight average molecular weight of the Kyberdrug in saline
solutions is of the order of 80,000-120,000, resulting in
80-120 particles of monomer molecular weight of 1,900
((m+Na]'). Thus, the total phosphate content or the ratio
of phosphate to glucosamine is constant and not at
variance, hence reflecting the equivalent total amount of
Kyberdrug per mL. The monomer molecular weight of the
Kyberdrug has been determined of these preparations by
MALDI-TOF mass-spectroscopy (matrix: 3.5-dihydroxy-benzoic
acid, or sinapic acid) and Fast-Atom-Bombardment (FAB)-
mass-spectroscopy with thioglycolic acid as a matrix in the
presence of butane and it has been found to be about 1900
daltons.
-73-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 3
The preparation of Kyberdrug according to Scheme
1 was followed. The number of cells can easily and with
confidence be determined by plaque test counting, since the
number of cells is proportional to the amount of Kyberdrug
released during the precise washing process with e.g. 0.154
M NaCl. For instance, a population of 109 cells per
Diagonal Agar releases after extensive washing 0.51475
mg/mL Kyberdrug in the presence of 0.154 M NaCl, or 0.5104
mg/mL Kyberdrug in the presence of 0.025% phenol,
respectively. The determinations of the final
concentrations of Kyberdrug can be performed through a
standard as mentioned in example 2, or by absolute dry
weight measurements using a ng-balance, or can be
controlled through standard phosphate determinations as
described in example 2.
-74-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 4
Kyberdrug-Lysine Complex
(a) Various Kyberdrug-Lysine complexes were
prepared as follows:
1.46 g (0.01 mol) L-(+)-lysine or D,L-lysine were
dissolved in 200 mL deionized water at 25 C; 500 ug or 1000
jig Kyberdrug, respectively, were each added to the
(L)lysine or D,L-lysine solution. The temperature was
raised to 40 C for a period of time of 2 hrs. The initial
turbidity of each of the solutions vanished after 30
minutes, and the resulting transparent solutions were
filtered through a 1G4 glass filter in order to remove any
particulate matter. The various solutions were
subsequently lyophilized. Yield: 1.95 g for 500 pg
Kyberdrug, or 2.42 g in case of 1000 pg Kyberdrug,
respectively. The product obtained was clear in a solution
in 0.154 M NaCl; it was odorless and colorless. Melting
point (under decomposition) m.p.= 156 C.
(b) The products of (a) were freeze dried. The
.flakes produced through freeze drying were pulverized to
small particles by means of a mortar. When milling in a
ball mill (Centrifugal Ball Mill model S 1000) in 30
minutes, a white powder was obtained which was free-
flowing. The mean particle size (AAAS 79 and AAAS 82) was
determined to be 5.0-6.0 pm through the use of a Coulter
Multisizer II, employing 0.9% sodium chloride solution;
however, the particle size can be increased to 50-60 pm.
(c) Preparation of a tablet:
A tablet is prepared containing 500 ug. The
inactive pharmaceutical ingredient consists of 1.0 mg
gelatin, 1.5 mg cross-linked sodium-carboxymethylcellulose,
-75-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
1 mg magnesium stearate in a total weight of 4 mg per
tablet.
The amount of gelatin was dispersed in water at
40 C, and the Kyberdrug-lysine complex previously mixed in
a mixer under low mixing capacity was also added at 40 C.
The resulting granules were dried in a drum roll at 40 C,
and subsequently sieved through a sifting machine having a
pore size of 1.6 mm. The final dried granulate was pressed
to a tablet having a final weight of 4.0 mg.
(d) The procedure of (c) was repeated except 1000
ug Kyberdrug is used as the active ingredient. The total
weight of the tablet was 4.5 mg.
-76-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 5
Kyberdrug -(-)-N-Methylglucosamine Complex
2.0 mg Kyberdrug and 1.98 mg (0.01mol) D-(-)-N-
methylglucamine were dispersed in 50 mL isopropanol/water
(50/50,v/v) at 20 C. The solution was heated to 50 C for 30
minutes until a clear and transparent solution was
obtained. Under continuous stirring and at 20 C, 50 mL of
water was added thereto. The solution was turbid; in
addition, a microcrystalline precipitate was formed which
was filtered off, and the supernatant was concentrated
until no more microcrystalline precipitate developed. The
combined microcrystalline precipitates were dried over P4010
in vacuum at 20 C. The final product was further dried in
an oven over silica gel at 25 C until no weight changes
were observed. Yield: 3.5 g. A tablet was formed using the
conditions pressed under similar conditions and inactive
ingredients as described in Example 4.
-77-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 6
Kyberdrug-Poly-L-lysine-Complex
0.15 mg poly-L-lysine (25.6kD) was dissolved in 5
mL 0.9% (w/w) NaCl at 20 C in the presence of 500 jig
Kyberdrug. The dispersed solution was sonicated (100W,
Branson Sonifyer) for 30 minutes until a transparent
solution was obtained. The resulting solution was purified
by Sepharose 2B column chromatography (1.0x10 cm) applying
a linear gradient ranging from 0.9% NaC1 (0.154 M) to 1.7 M
NaCl (25 C). The flow rate was maintained at 10 mL/h, and
optically active fractions were monitored by 220 nm and/or
by means of refractometry (550 nm) using an Abbe
Refractometer (Zeiss). The peak eluting at a salt
concentration of 0.75 M NaCl contained the Kyberdrug-poly-
L-lysine complex according to chemical analysis and
phosphate determination, respectively. The optically active
fractions were pooled, lyophilized and stored over Silica
Gel in a desiccator at 20 C. Yield: 0.1-0.12 mg dry weight.
-78-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 7
Poly-L-lysine-double chained cationic lipid-
Kyberdrug-complex 0.15 mg of poly-L-lysine (25.6 kD) was
mixed with 0.5 mg distearyldimethylammonium hydroxide
(DSDMAOH) in 5 mL water at 25 C.'To the clear solution, 500
jig Kyberdrug, which was dispersed in 1.0 mL of 0.154 M
NaCl, was added. The resulting product was heated to 30 C
for 30 minutes. A turbid solution resulted. The turbid
solution became transparent upon'sonication (100W, Branson
Sonifyer) for 5 minutes. The solution was filtered through
a Millipore Filter (0.9 um) and subsequently lyophilized.
The lyophilized material containing NaCl was dissolved in
water (2 mL) and dialyzed against 100 ml deionized water at
25 C, applying several changes of the dialyzing water. The
solution in the dialysis bag was lyophilized,'and stored
over Silica Gel at 20 C. No decomposition. of this material
was observed at 20 C to 30 C,. Yield: 0.92 mg poly-L-
lysine-DSDMA-Kyberdrug-complex.
-79-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 8
Cationic-Kyberdrug-Liposome Complex Preparation.
A mixture of Dioleoyl-phosphatidylcholine and
dioleoyl-trimethylammonium propane was prepared in a 1:1
(w/w) ratio of 10 mg/mL in a chloroform/methanol solution
(1:1 v/v). This was used as a stock solution. To this
solution, 500 or 1000 pg Kyberdrug dissolved in 0.154 M
NaCl was added with continuous stirring at 25 C, in order
to ensure complete and intensive mixing of the two phases.
The obtained solution was separated.into both the organic
and aqueous phases. The organic phase was washed with
deionized water, separated again, and the organic phase
dried over CaCl2. This solution was diluted with the stock
solution until the volume was 100 mL, and then the diluted
Kyberdrug solution was subsequently sonicated to obtain a
transparent dilute solution of Kyberdrug. The
concentration of the Kyberdrug in the liposome was further
diluted to 100 mL with chloroform/MeOH (1:1, v/v), dried
under nitrogen in a narrow glass beaker, and subsequently
desiccated under vacuum for 12 hours. After the addition of
1.0 mL deionized water (Millipore water), and 4 hours
incubation at 37 C, the vesicle suspension was sonicated
again to clarify for 10 minutes. The resulting solution of
cationic liposomes containing 15 mg/mL material including
the desired concentration of Kyberdrug was filtered through
0.2 pm Nucleopore-filters. For optical measurements the
concentration of single unilammellar vesicles applied was
between 0.1 to 0.25 mg/mL. The cationic liposome-Kyberdrug
complex containing e.g. 500 pg Kyberdrug sizes was measured
by dynamic light scattering (ALV 5000, Langen, FRG). The
determined size distribution ranged between 0.02 to 0.1 pm
in diameter with a peak around 0.085 pm. [Note: The
-80-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
Kyberdrug in aqueous solution has a size distribution
around 0.6 pm in the presence of 0.154 M NaCl, or in
organic solvents (such as chloroform, methanol, and the
like or mixtures thereof); the sizes were measured at 0.002
pm, indicating that the Kyberdrug is completely differently
orientated with regard to size and form in the cationic-
liposome-Kyberdrug complex, when compared to the highly
aggregated state of the Kyberdrug in aqueous solution.]
The material with the encapsulated Kyberdrug in the desired
concentrations of Kyberdrug in the liposomal preparation
was stored at -20 C without any deterioration of the
preparation. The solution was stable over two years time
when stored at 20 C under nitrogen in the absence of any
environmental radicals or outside contaminations,
respectively.
-81-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 9
Cationic-Kyberdrug-Liposome Complex Preparation using
synthetic cationic lipids.
A mixture of dioleoyl-phosphatidylcholine and
distearyldimethylammonium hydroxide (DSDMAOH), or
dihexadecyldimethylammonium hydroxide (DHDMAMOH) were mixed
together in a 1:1 (w/w) ratio in 60% chloroform/40% MeOH
.(w/w), or in neat chloroform or cyclohexane, respectively
at 25-30 C. 1000 ug Kyberdrug dispersed in 0.154 M NaCl (10
mL) was added to 20 mL dioleoyl-phosphatidylcholine/
(DSDMAOH) or (DHDMAMOH), respectively, under continuous
stirring at 40 C and a N2-stream until the two phases
separated. This separation of the phases was almost
instantaneous. The aqueous phase contains the inorganic
material only, whereas the organic phase contained the
Kyberdrug-liposome-complex.
-82-
CA 02436107 2003-04-04
WO 02/28424 PCT/IBO1/02284
EXAMPLE 10
Encapsulation of Kyberdrug in L-(+)-Lysine-dipalmitoyl-a-
phosphatidylpropanolamine liposomes.
Covalent coupling of L-(+)-lysine to dipalmitoyl-)-a-
phosphatidylpropanolamine or di myristoyl--)-a-
phosphatidylpropanolamine, respectively, was accomplished
by reacting 1,1-(dimethylethoxy)carbonyl-succinimidyl-L-
(+)-lysine, which was dissolved in 1 mL chloroform/MeOH
(1:1, v/v) containing 0.5 umol triethylamine with 100 Umol
dipalmitoyl-)-a-phosphatidylpropanolamine. The reaction was
carried out at 60 C for 6 hours. Thin layer chromatography
(TLC) analysis (Silica Gel H, solvent
chloroform/MeOH/water, 65:25:5) of the reaction mixture
revealed quantitative conversion, confirmed also by HPLC-
analysis on a RP-18 column. After removing the solvent
system and remaining unreacted material, e.g. 1,1-
'(dimethylethoxy)carbonyl-succinimidyl-L-(+)-lysine, the
purified BOC-L-(+)-lysine-BOC- dipalmitoyl-)-a-
phosphatidylpropanolamine was treated with 5 mL
chloroform/trifluoroacetic acid (30:70). The mixture was
gently stirred for 3 hours at 20 C, the solvent was removed
under vacuum, and the residue was dissolved in chloroform.
The deprotected product was analyzed by TLC, and
phosphorous content, R. = 0.41 (CHC13/MeOH/H20: 50:40:10).
The lysinyl- dipalmitoyl-)-a-phosphatidylpropanolamine was
purified by carboxymethyl-cellulose (CM 52, Whatman) using
CHC13/MeOH as elution solvent, or acetonitrile/MeOH in a
ratio of 95:5. The product eluted in 15% MeOH, and was
lyophilized and was stored at -20 C under N2 where over the
time of 1 year no deterioration of the material has been
detected.
-83-
CA 02436107 2009-07-31
Liposomes of this material containing 1000 g Kyberdrug was
prepared in the usual way by probe sonication and
dispersing in a buffer containing e.g. 10 mM TRIS-HC1, pH
7.0 -7.4 (20 C) in the presence of 0.154 M NaCl. The
determination of the encapsulation efficiency with respect
to Kyberdrug concentration and leakage etc. was determined.
by extracting the Kyberdrug with I% (w/w) TRITON X I OOTM, and
subsequently analyzing the phosphorous content or the
characteristic peak distribution in MALDI-TOF-mass--
spectroscopy with 2,5-dihydroxy benzoic acid as a matrix,
The stability of the 1Cyberdrug loaded liposomes was assayed
under three different conditions; in the preparation buffer
as described above at 4 C at various times; in a culture
medium with or without calcium or magnesium (MEN 500 or MEN
400, respectively; ref: Gibco) and with or without 5% (v/v)
fetal bovine serum after 4 hours incubation at 4 C, and in
human plasma after incubation at 37 C. For all conditions
.the loaded liposomes were treated with Triton x 100 or with
desoxycholate after incubation, and fractionated by column
chromatography (Sepharose 2B), or by HPLC as described
before.
84
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 11
Conductive skin gel containing Kyberdrug
The gel is prepared by mixing the contents of A,
B and C together.
Ingredients % by Weight
Part A
Deionized water 68.00
Carbopol ETM 2001 Resin 0.85
Potassium hydroxide 0.05
Propylene glycol 15.00
Part B
Deionized water 10.0
Disodium EDTA 0.05
Carboxymethylcellulose (2%) 15.00
Potassium hydroxide 0.50
Part C
Kyberdrug 1000 jig
Propylene glycol remainder
-85-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 12
Antipruritic Spray containing Kyberdrug
A spray was prepared by mixing together the
following ingredients:
Ingredients % by Weight
CarbopholTm 041 NF Resin 0.60 =
Kyberdrug 2000 ug
Ethanol 50.00
Glycerol 20.00
Water q.s.
Total 100%
pH 6.15
This translucent, non-greasy aerosol preparation with
Kyberdrug as an active ingredient is easy to dispense. It
is designed to provide effective symptomatic relief of pain
and itching associated with skin irritations and allergies.
-86-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 13
Anti-inflammatory gel in the presence of Kyberdrug
The gel was prepared by mixing the following
components:
Ingredients % by Weight
Kyberdrug 2,000 jig
Carbophol 9345 NF Resin 2.00
Tris Amino 4.000
Deionized water q.s.
Total 100.00%
Properties
pH 7.35
Viscosity 75,800 cPs
-87-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
In Experiments 14-17, a Kyberdrug was isolated in
accordance with the procedure described herein. The
chemical analysis performed in the isolated Kyberdrug in
all four examples were performed through alkaline and
acidic hydrolysis under strictly controlled conditions
enzymatic hydrolysis according to general chemical and
biochemical standard procedures. The methods for analysis
were MALDI-TOF-MS, matrix assisted laser desorption
ionization mass spectroscopy and ion-spray mass
spectroscopy, respectively. The matrices used are DHP(3,5-
dihydroxybenzoic acid) and 2-cyano-4-hydroxy-cinnamic acid.
The mass spectra of MALDI-TOF were recorded in the positive
and negative ionization mode for detection.
-88-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 14
Using the procedure described herein from the
cultures of E-soli bacteria isolated from the urine and
feces of patients suffering with symptoms of otitis media,
a mixture was isolated. It was then subjected to the
chemical analysis, described hereinabove.
The product isolated had the following structure;
identified as Compound 1.
H
ORi O
H
.O
H .0 NH OR
OH
OH
0 (1)
HHH HHH
HHH H
HHH
0
II
wherein R is hydrogen or -P-OH or salt thereof.
0
The isolated product was a mixture of about 80%
(w/w) unphosphorylated glycolipid and about 20% (w/w) mono-
phosphorylated glycolipid, where the inorganic phosphate is
located at the 1-position or the 4'position at the other
end of the disaccharide. A small amount of 1,4-
diphosphoryl product of glycolipid was also isolated.
-89-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 15
Using the procedure described herein, from the
cultures of E-coli bacteria isolated from the urine and
feces of patients suffering from sinusitis, a mixture was
isolated. It was then subjected to the chemical analysis
described hereinabove.
The product isolated had the following structure,
identified as Compound 2.
H
ORS
H 0
NH2 OR
HO
OBI
* OBI
(2)
HHH
HHH
0
lI
wherein R is hydrogen or -P-OH or salt thereof.
0
The isolated product was a mixture of about 80%
(w/w) unphosphorylated glycolipid and about 20% (w/w)
monophosphorylated glycolipid, wherein the inorganic
phosphate is located at the 1-position or the 4'position at
..90-
CA 02436107 2003-04-04
WO 02/28424 PCT/IB01/02284
the other end of the disaccharide. A small amount of 1,4'-
diphosphorylated product of the glycolipid was also
isolated.
-91-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 16
Using the procedure described herein, from the
cultures of E-coli bacteria isolated from the urine and
feces of patients suffering from chronic rheumatism
(osteoarthritis), a mixture was isolated. It was then
subjected to the chemical analysis described hereinabove.
The product isolated had the following structure,
identified as Compound 3.
H
ORi
O O OR
NH 0 NH
OH OH 0.
* OH * OH (3)
HHH' HHH
HHH HHH
0
II
wherein R is hydrogen or -P-OH or salt thereof.
O
The isolated product was a mixture of about 80%
(w/w) unphosphorylated glycolipid and about 20% (w/w)
monophosphorylated glycolipid, wherein the inorganic
phosphate is located at the 1-position or the 4'position at
the other end of the disaccharide. A small amount of 1,4'-
-92-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
diphosphorylated product of the glycolipid was also
isolated.
-93-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 17
Using the procedure described herein; from the
cultures of E-coli bacteria isolated from the urine and
feces of patients suffering from asthma bronchial, a
mixture was isolated. It was then subjected to the
chemical analysis described hereinabove.
The product isolated had the following structure,
identified as Compound 4.
H
OR, 0 0
O H
NH2 0 NH2 OR
OH
(4)
H H H
HH
HHH
0
II
wherein R is hydrogen or -P-OH or salt thereof.
II
0
The isolated product was a mixture of about 80%
(w/w) unphosphorylated glycolipid and about 20% (wlw)
monophosphorylated glycolipid, wherein the inorganic
phosphate is located at the 1-position or the 4'position at
the other end of the disaccharide. A small amount of 1,4'-
-94-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
diphosphorylated product of the glycolipid was also
isolated.
-95-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
As shown hereinabove four different products were
isolated. These products are modified free-lipid A
molecule. The product contain a mixture of about 80% (w/w)
unphosphorylated glycolipids and about 20% (w/w) of the
corresponding monophosphorylated glycolipids, wherein the
inorganic phosphate is located at the 1-position or the 4'-
position at the other end of the disaccharide. The sugar
component of the disaccharide in all four examples is the
N-acylated glucosamine. To some extent, a small amount of
the 1,4'-diphosphorylated product of the glycolipid was
also present. The hydroxyl at C-6 is free, it is not
acylated or bound to another component, e.g., amino acid
residue or another sugar component.'
Various stereoisomers of Compounds of 1-4 are
contemplated to be within the scope of the present
invention; the varius chiral centers are marked with an
asterik and each chiral center may be in the R or S
configuration. However, it is preferred that all of the
chiral centers so marked are in the R configuration.
The unphosphorylated Compounds 1-4 can be separated
from the phosphorylated compounds by techniques known to
one of ordinary skill in the art, such as by
chromatography, column chromatography HPLC, and the like.
Once separated, other ratios of unphosphorylated compounds
to monophosphorylated compounds can be prepared. It is
preferred that the weight ratio of the Compounds 1-4 range
from about 90:10 of the unphosphorylated glycolipid to the
corresponding mono phosphorylated compounds to about 60:40,
and the most preferred ratio is 80:20.
The unphosphorylated Compounds 1-4 as well as the
phosphorylated Compounds 1-4 may also be present as
pharmaceutically acceptable salts. Examples include
-96-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
pharmaceutically acceptable metal salts, e.g., especially
Groups 1 and 2 metal salts, e.g., sodium, potassium,
calcium, magnesium and the like.
In the aggregate, these mixtures isolated in
Examples 14-17 will form Kyberdrugs, as defined herein.
The mixture isolated in Examples 14-17 exhibit the
utilities of the Kyberdrugs described herein.
-97-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EXAMPLE 18
78 patients in a multicenter study who were
suffering either from cough and cold or sinusitis and
infectious pulmonary systems were treated with Kyberdrug,
isolated therefrom using the procedure described herein.
The Kyberdrugs daily under the supervision of a medical
doctor for four weeks. They all received the same dosage
regime, either a daily dose of 100 ug/ml parenterally or
200-300 ug/mL subcutaneously or 1000 ug/ml.
All patients recovered significantly and
individually without increasing the dose. In addition,
eight different cytokines were analyzed, and their changes
during the period of therapy were monitored before, during
and at the end of the therapy. In addition, these
cytokines were monitored in patients with light symptoms
of the above mentioned infections who were not receiving
Kyberdrug. Particularly, the observed changes in
concentration of cytokines was determined before, during
and after the treatment with Kyberdrug. Fig. 2 shows the
relative changes in concentration of interleukin-103 in
patients which were not treated with Kyberdrug and those
treated with Kyberdrug. In the graph, the line indicated
by (0-0) are those corresponding to the untreated patient
and the line indicated by (= =) are those treated
with Kyberdrug for 4 weeks. It is clearly seen that the
number of colonies per volume before and after the therapy
increases rapidly between 105 to 106 colonies per mL, and
the concentration of interleukin-10 in the patients' serum
raises from 250 pg/mL up to 1,500 and higher in pg/mL. This
is consistent with an exponential increase of interleukin-
through stimulation of the Kyberdrug by a magnitude of
almost 100 pg/mL which is equivalent to 105 cells per mL,
-98-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
indicating a very high therapeutic index and stimulation
index. This is also confirmed through in vitro and in-vivo
experiments using human blood specimens under the same
assay conditions.
Bioassays for IL-1R and IL-10 were performed as
ex-in vitro test using patient's serum. Bioassays for IL-
la and R commonly utilize the ability of these cytokines to
induce IL-2 production by T-cell lines such as EL4.6.1 and
LBRM, or in primary cultures of thymocytes (LAF assay). A
typical assay system is shown in the protocol 1 and
protocol 2, respectively attached hereto in the appendix.
These assay systems are very close to the protocols
published by M. Wadhwa, C. Bird, L. Page, A. Mire-Sluis and
R. Thorpe, in "Cytokines, A Practical Approach", 2d ed.,
edited by F.R. Balkwill, IRL-Press at Oxford University
Press, 1995, pp. 358-361. The protocol for IL-10 is
essentially the same as offered by M.Wadhwa, et al. in the
same book at pages 368-369.
Fig. 3 shows a significant decrease of
interleukin-1R within the same colony population with
respect to numbers of Kyberdrug before and after therapy
with the autovaccines. The line (0-0) is the concentration
of interleukin B before treatment, while
( =) represents the concentration thereof after
treatment. A significant exponential decrease of the
relative production of interleukin-l(3 was observed in the
serum of patients treated with the Kyberdrug, which is
invariant to the increase of interleukin-10. The
differences or the modulation of the different cytokine
biosynthesis under the treatment with Kyberdrug within this
dosage regime with respect to these groups of patients is
shown in Fig. 4., revealing also the changes in numbers and
-99-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
absolute values before therapy and after therapy,
respectively. In the experiment described in Figure 4, 275
patients suffering from sinusitis were treated with 100 ug
subcutaneously. The change in the interleukines are
graphically depicted before treatment (= =) and after
treatment (-) for 4 weeks. As clearly shown, the various
concentrations of interleukines changed before and after
therapy. This was also confirmed through in-vitro studies
in human blood samples by determining the increase of
interleukin-10 after administration of Kyberdrug; it showed
high stimulation index of more than 14 at 2.0 micrograms/ml
of Kyberdrug, which is a magnitude lower than the usual LPS
as a reference sample. These clinical examples verify the
usefulness of the Kyberdrug in the treatment of various
diseases, e.g. cough and cold, bronchitis or sinusitis as
well as rheumatism, where similar factors were modulated or
stimulated through the Kyberdrug by exerting their
inhibitory actions during the infectious pathway, or
exacerbation of osteoarthritis, which is followed by a
relief of symptoms caused by the disease and welcomed by
the patients.
For instance, patients suffering from
osteoarthritis (N=14, average age 55), who received a daily
dose of 100 ig of Kyberdrug subcutaneously (in the morning,
after breakfast), i.e., over a period of four weeks
reported a relief of symptoms, particularly in the joints
and a significant pain relief. As a result, a significant
reduction in nonsteroidal anti-inflammatory medicament
e.g., normally in the amount of 50-60% in case of ibuprofen
or S-(+)-naproxen, of the daily dose were observed. In
addition, the exacerbation of this form of rheumatism was
significantly reduced, which could be strongly correlated
-100-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
with the measured interleukins and cytokines by clinical
blood tests from these patients with the tests used above.
The ex-in vitro tests of these patients treated with
Kyberdrug reveal normally all the same pattern as shown in
Figure 3.
The Kyberdrug causes changes in the
concentrations of various cytokines, e.g., enzymes such as
protease inhibitors. This same change in interleukin
concentrations has been seen in patients who have been
suffering from rheumatic diseases or fractures, contusions,
chronic rheumatic pain, osteoarthritis, spondylitis,
fibrositis, neuritis or infectious diseases caused by
streptobacteria or staphylobacteria and treated with
Kyberdrug.
Without wishing to be bound, it is believed that
Kyberdrug influences the transformational properties of
cells and their agglutininability through the stimulation
of the protease. It is believed that the administration of
Kyberdrug induces proteolysis of previously unmasked and
inaccessible membrane lectin-binding sites, which is the
reverse process of action of the protease inhibitory
system. On the other hand, the protease inhibitors systems
induce lectin agglutinability in normal cells. Moreover,
they are associated with the agglutination of transformed
cells (tumor), and mimic the effects of exogenous plant
lectins on the control of cell growth. When the Kyberdrug
is administered in vitro to the cells, the cells become
nonagglutinable and cell division is considerably retarded.
It has also been observed that the administration
of Kyberdrug results in the loss of normal restriction of
cell mobility that accompanies cell transformation and
protease treatment. Fibroblast migration into wounds is a
-101-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
plasmin-dependent process, which is suppressed by protease
inhibitors. When Kyberdrug is administered, fibroblasts
have the capacity to ingest particles and display Fc
receptors. They, therefore, appear to be susceptible to
immune complex activation of protease production.
Polymorphonuclear leukocyte chemotaxis, exocytosis,
phagocytosis, and superoxide anion generation are typically
protease-dependent processes, and hence the influence of
the Kyberdrug can be studied, including lab-tests of
patients suffering from chronic rheumatism. It has been
postulated that the superoxide, particularly the H00- anion
(H.H.Paradies et al., Apotheker-Zeitung, 126, 477-483,
1985; H.H.Paradies et al., J. Eur.Med. Chem., 25, 143-156,
1990; H.H.Paradies &K.E. Schulte, Ann. New York Acad. Sci.,
Vol. 529, 221-228, 1988) has been found to be one of the
main factors in the pathogenesis of inflammatory arthritis
and is responsible for the reduced response of rheumatoid
synovial fluid lymphocytes to plant mitogens or
nonsteroidal antirheumatic drugs. T cells are more
sensitive to the effects of the superoxide anions and H00-
than the B cells. However, when effective amounts of
Kyberdrug are administered the i.) superoxide and H00
anions are present in negligible concentrations, ii.)
surprisingly the concanavalin A responsive lymphocyte
(suppresser cell) is no more sensitive than when treated
with concanavalin A alone, iii.) superoxide dismutase
(SOD), which is present in negligible amounts in synovial
fluid, particularly in patients suffering from inflammatory
arthritis, does not inhibit the suppresser effect of the
superoxide anions on lymphocyte function, but it does
surprisingly during the treatment with Kyberdrug.
-102-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
Furthermore, surprisingly it has been found that
Kyberdrug has a certain auto-esterase activity which is
specifically regulated through the stimulation of
interferon and interleukins; when released during an
inflammatory process these interferons and interleukins
enhance, in addition to the esterase activity, both natural
and interferon-stimulated killer cell activity due to a
surface active manner on part of the Kyberdrug.
Thus Kyberdrugs inhibit the aggregation of IgE
molecules on the mast cell surface and hence reduce the
release of histamine, serotonin, heparin, proteases and
further inhibits the release of slow reacting release
substances of anaphylaxis e.g. leukotrienes and
prostaglandins. Kyberdrugs are able to regulate according
to this mechanism, the occurrence of,C-reactive protein in
serum of patients with chronic inflammation.
Circulating proteases which are mitogenic for
fibroblasts and those which are characteristic for chronic
inflammatory processes have been noted in patients with
osteoarthritis and scleroderma. This effect is regulated by
Kyberdrug particularly in severe cases of osteoarthritis.
It is believed, without wishing to be bound, that this is
attributable to its unique molecular conformation. The
Kyberdrugs may be regarded as a substance that is capable
of inactivating cytotoxic agents present in the serum of
the patients, and thus preventing endothelial cells from
being attacked by these cytotoxic endogenously produced
substances. Without wishing to be bound, it is believed
that a possible role for the stimulation of the proteases
through the Kyberdrug in the acute inflammatory reaction is
the infiltrate response to dermal thiol proteinase
'injection and the protease-induced increase in chemotaxis
-103-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
and exocytosis as well as superoxide or HOO- anion
generation. It is believed, without wishing to be bound,
that the infiltrate response is due to the size, charge and
shape dynamics of the Kyberdrug, while the increase of the
chemotaxis as well as the increase in enzymatic activity of
the protease is also mainly due to the Kyberdrug.
Inflammatory synovium contains increased elastase activity
.that is capable of cartilage degradation, which is
significantly decreased or abolished under treatment with
Kyberdrug. Chondrocyte-induced cartilage destruction by
collagenase and proteoglucanese which are metalloproteins
is "down-regulated" by the Kyberdrug due to enzyme
inhibition.
Without wishing to be bound, it is believed that
the Kyberdrug regulates inhibitory protease activities
endogenously by a decreased cytotoxic lymphocyte activity,
including both antibody-dependent cell-mediated
cytotoxicity and natural killer cell activity. Furthermore,
the action of the Kyberdrug as inhibitor of proteases in
enhancing macrophage inhibitory factor activity enhances
also macrophage surface adherence, phagocytosis, and tumor
cytotoxicity. Moreover, the polymorphonuclear leukocyte
chemotaxis, phagocytosis, degranulation, and superoxide or
HOO- generation are surprisingly Kyberdrug-sensitive
processes. Thus diseases caused by these radicals can be
treated with the Kyberdrug. The Kyberdrug also reduces
endogenously and stimuli-related superoxide and H0O-anions
generated by alveolar macrophages, peripheral blood
mononuclear cells, polymorphonuclear leukocytes, and
basophils. The Kyberdrug exhibits also sialoprotein-
related antigenicity as noticed from in vitro and in vivo
studies of patients suffering from cold & rhinitis,
-104-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
respectively, as determined from in vitro studies applying
the hemagglutenin test, which measures the competition of
the Kyberdrug with the cell surface, sialyl-oligosaccharides
for viral hemagglutenin binding, and the infectivity test,
which measures the reduction of plaque reduction in MDCK
cells (Madin-Carby Canine Kidney) after or prior to
infection with influenza A virus. Inhibition of influenza
A virus plaque test assays were performed according to K.
Tobita, et al., Med. Microbiol. Immunol., 1975, 162, 9-14;
Hayden, F.G., Cote, K.M., Douglas, R.G., Jr., Antimicrob.
Ag. Chemoth., 1980, 17, 865-870. Specifically, MDCK cells
were inoculated with influenza A/PR/8/34 (ATCC, Rockville)
and diluted in Eagle's minimal medium, pH 7.3-7.5,
containing 4 ug/mL trypsin to yield approximately 50
plaques per well. The cells were left for 1 h at 25 C for
the virus to absorb, subsequently overlaid with cell growth
medium (DCCM-1, Boehringer Mannheim, FRG) containing 1%
agarose, 2 pg/mL trypsin, 0.001% DEAE-dextran (Pharmacia),
and the amount of Kyberdrug to be tested. After 72h at
32 C, plaques were visualized by fixing with 2.5%
glutaraldehyde followed by staining with carbol fuchsin.
The percentage inhibition of plaque formed in the absence
of any Kyberdrug, were calculated for each inhibitory
Kyberdrug concentration. The mean % inhibition values from
these experiments in triplicate were used to estimate the
inhibitory concentration at 50%. Depending on the presence
of specific counterions, e.g., Caz+ or Mgt+, respectively the
ICS0 were found to be in the range of 10 ',ig/mL to 50 pg/mL
Kyberdrug. The hemagglutenin-inhibition test (a standard
test) was performed according to G.N. Rogers, T. Pritchett,
J.L. Lane and J.C. Paulson, Virology, 1983, 131, 394-408.
The IC50 values for Kyberdrug were in the range of 2.0 dig/mL
-105-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
to 0.2 pg/mL, depending on the addition or absence of Zn
gluconate (0.0010), respectively.
a-2 macroglobulin is also a pivotal protease
inhibitor which is regulated by the Kyberdrug. a-2
macroglobulin functions as a carrier protein in transfer of
proteases from other inhibitors such as the a-l-antitrypsin
protease inhibitor, and has a protective function against
the activity of other more specific inhibitors e.g.
protecting plasmin from antithrombin III neutralization,
plasmin-sensitive surface-associated fibronectin molecules
on fibroblasts from degradation, and/or papain destruction
of cartilage ( D.A.Lewis, "Endogenous anti-inflammatory
proteins", Biochem. Pharmacol., 26, 693, 1977) Since a-2-
macroglobulin is an important mechanism for clearance of
immune complexes in joint fluid, the subsequent clearance
of such complexes by macrophages with any enhancement of
the inflammatory processes is believed to be through the
action of macrophage activation and plasminogen release.
Although the spectrum of a-2- macroglobulin has some
similarities to that of the a-l-antitrypsin protease
inhibitor, it is surprising that reactions with trypsin are
considerably stimulated through the Kyberdrug in a much
faster way than with the a-1-antitrypsin protease
inhibitor, and are unaffected by heparin, but are affected
strongly by the Kyberdrug. This is in contrast to the
heparin inhibition of a-2-macroglobulin-thrombin complex
formation since Kyberdrugs do not bind to thrombin, but
heparin does. a-2- macroglobulin is localized on.
endothelial surfaces and can regulate activities of
adherent cells and reduce inflammatory response. Since the
Kyberdrug stimulates the a-2- macroglobulin, the inhibition
of the carrageenan, histamine, prostaglandin E2, serotonin,
-106-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
and bradykinin induction in inflammation can be reconciled
in conjunction with the very sensitive parameters measured
before. The relative proportions of free and complexed a-2
macroglobulin with the Kyberdrug determines the biologic
effects which have been observed in patients with
inflammatory diseases. Furthermore, the stimulation of a-2
macroglobulin through the Kyberdrug derived from patients
with rheumatoid arthritis is shown through the activity of
polyclonal B cell activator. a-2- macroglobulin from
healthy individuals does not manifest this activity, but
patients with rheumatoid arthritis do, so it can be
reconciled that the Kyberdrug is responsible for the
polyclonal B cell activation, and the a-2- macroglobulin-
proteinase complexes for macrophage activation.
Furthermore, inherent a-2-macroglobulin antigenic
determinants when stimulated by the Kyberdrug are also
responsible for the ability of the Kyberdrug to diminish
the survival of bacteria in humans. The organism's
mechanism due to the support of the Kyberdrug has to be an
important factor since it must produce excess proteases to
overcome blood inhibitors. The presence of a "blind"
intestine necessitates reflux of the excess proteases which
can produce additional a-2-macroglobulin complexes as they
diffuse from the infected site. The immunsuppressive effect
of such complexes in the absence of Kyberdrug is a factor
in persistent infestation, and provides a continuous
incident of inflammation and.infection, respectively.
Moreover, the importance of free a-2-
macroglobulin is reflected in the observation that
saturation of a-2- macroglobulin in the circulation or
abdominal cavity is normally followed by shock and death
which can be prevented through the administration of these
-107-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
Kyberdrugs. Furthermore, the degree of saturation of this
particular inhibitor seems to be a life threatening
determinant, so the sensitive balance is introduced through
the administration of the Kyberdrug. Accordingly only about
15 ug of trypsin is required per milligram of a-2
macroglobulin for the Kyberdrug to be fully complexed. The
Kyberdrug itself as well as the complexes comprising
Kyberdrug and a-2 macroglobulin have a key role in
preventing autodigestion including the protection of the
gastric and intestinal mucus.
Deficiencies of a-2- macroglobulin has been found
in patients with respiratory distress syndrome, sepsis
including consumptive coagulopathy, regional enteritis,
multiple myeloma, in small-for-gestational-age infants, or
under streptokinase therapy. Moreover, a-2 macroglobulin
levels are also depressed when plasmin is generated in vivo
but do not become depressed'in thrombotic states, or in the
presence of Kyberdrug, respectively. The presence of a-2-
macroglobulin in the lung, normally lower than 25% than
that found in the serum, explains the lack of protective
effect of a-2- macroglobulin in the early onset of
emphysema, which can now been avoided through the
administration of Kyberdrug. Depressed levels as being
observed in respiratory distress syndrome, and the failure
of patients with a-1-antitrypsin deficiency to develop
emphysema suggest that the role of a-2 macroglobulin is not
inconsequential including the regulatory effect of the
Kyberdrug.
Serum levels of a-2 -macroglobulin have been
reported to be almost normal in patients with rheumatoid
arthritis, even when serum a-2-globulin levels are elevated
(J.R. Ladd & J.T. Cassidy, " Serum and synovial fluid
-108-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
concentrations of a-2-macroglobulin in patients with
rheumatoid arthritis", Arthritis Rheum., 12, 309, 1969). In
addition a significant proportion.of a-2- macroglobulin in
synovial fluid of patients with rheumatoid arthritis or
degenerative arthritis has been found to be functionally
inactive due to binding of synovial fluid enzymes such as
collagenase and cathepsin, which can be shown to be
reversed in the presence of Kyberdrug.
Kyberdrugs also suppress inflammatory arthritis.
In inflammatory arthritis, a-2 macroglobulin inhibits
synovial collagenase which degrades the collagen triple
helix, cathepsin D degrades proteoglycans, and cathepsin A
degrades both. These degradation processes are
significantly inhibited in patients with rheumatoid
arthritis after administration of Kyberdrug. Furthermore,
the role and the modulation of the a-2 macroglobulin in _
limiting autodigestion of endothelial surfaces which occurs
in the presence of free plasmin are significantly reduced
in the presence of Kyberdrug, and is of importance of the
vasculature in the pathogenesis of collagen vascular
disease.
Another factor being modulated through Kyberdrug
is antithrombin III, which is an inhibitor of a number of
enzymes that, along with their other functions, modulate
fibrinolysis and complement systems, which is important in
this context of the invention. The more direct
immunomodulation has been observed for antithrombin III
together with Kyberdrug in the course of inhibition of cell
division and mitogen-induced T-cell proliferation possibly
reflecting inhibition of thrombin. Antithrombin III, when
stimulated by the Kyberdrug, enhances the stimulation of
-109-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
the macrophage activation factor and in response thereafter
the macrophage migration inhibitory factor.
Inhibitory effects of Kyberdrug on Retroviruses.
Another unexpected effect of the Kyberdrug which
has been observed is the inhibitory action in lymphocyte
cell cultures which has been infected with the human
immunodeficiency viruses type 1 & 2 (HIV 1 & 2) from blood
of an AIDS patient, and which has been determined through
assay systems for virus production (load) and infectivity.
The course of the infection was monitored by i.) the amount
of HIV particles by quantitatively assaying virion-
associated protein directly, e.g. p24 antigen capture or
indirectly through the reverse transcriptase activity (RT),
and the gp120 glycoprotein; ii.) particle infectivity using
TCID50 (tissue culture infectious dose, half-maximal)
determinations, and the syncytium formation (SCF) assay.
The advantages of using the p24 antigen capture assay, the
RT-assay as well as the gp120 protein assay is related to
the sensitivity and quantitation possibility in order to
assess quantitatively the changes of particle associated
proteins including their concentrations vs. concentration
of the Kyberdrug. The RT-assay is known to be less
sensitive than the p24 antigen capture assay, but found to
be as sensitive as the gp120 assay. The assay systems are
those as described in the scientific literature and
regarded as the state of art, specifically in."HIV, Vols.
1&2, A Practical Approach, Virology and Immunology", edited
by J. Karn, PAS-Series, IRC-Press, Oxford University Press,
1995, and as described in the German Patent DE #196 32
823.3 by Zimmermann & Paradies (1997). In addition a
modified anti-HIV assay system was also used with
-110-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
application-of the MTT method introduced by R. Pauvels et
al., J. Virol. Methods, 20, 309, 1988. MT-4 cells which is
a human T4-positive cell line carrying human T-lymphotropic
virus type 1 were infected with HIV-IHTLV-IIIB at the
multiplicity of 0.01, and HIV-1 and mock-infected MT-4
cells were incubated in the presence of various amounts of
Kyberdrug (pg/mL) for 4 days at 37 C in a CO2 incubator. The
viability of both HIV-1 and mock-infected MT-4 cells was
assayed spectrophotometrically via the reduction of 3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium (MTT). The
anti-HIV activity is represented as the IC50, which denotes
the concentration needed for the inhibition of 50%
infection of MT-4 cells from HIV. The cytotoxicity
concentration CC50 was determined by the 50% cytotoxic
concentration of the test material on the MT-4 cell. A
modified RT assay system has been used on the basis of
these infected lymphocytes. Furthermore, in order to show
that the Kyberdrug are devoid of anticoagulant activity,
this activity was evaluated using bovine plasma in
accordance with the modified procedure described in
(K.Hatanaka et al., J. Med Chem., 30, 810, 1987, using
dextran sulfate as a standard having an anticoagulant
activity of 25 units/mg as a reference.
The HIV-envelope glycoprotein, gp120, has a
distinct secondary structure consisting of six a-helices in
which four of the six a-helices, i.e. al, a4, a5 and a6 were
found in the conserved Cl, C4 and C5 regions, and two other
helices, i.e. a2, and a3 were found in the V2 region and
pseudo-conserved C3 regions (J-F.Hansen et al.,- Proteins,
25, 1, 1996; L.Ratner et al., Nature 313, 277, 1985). In
light of the results obtained for the Kyberdrug with regard
to the protease inhibitory and stimulating effects in
-111-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
patients receiving Kyberdrug either as oral forms or
parental, it is believed without wishing to be bound, that
the Kyberdrugs block the action of the HIV-specific
protease enzyme during viral replication. Protease cuts the
viral proteins which is formed from the viral genetic
material into shorter chains. This is essential for
successfully assembling new viral particles in the host
cells. Therefore, protease inhibitors attack the HIV
particle at a later stage in its replication cycle than the
reverse transcriptase inhibitor which prevents virus
replication of its genetic material once it has entered the
host cell.
Without wishing to be bound it is believed that
the Kyberdrug acts as an non-competitive inhibitor with a
K,,, value of 500 dig and k at = 20 min-1 and decreases without
any significant influence on the value of Km,. However, a
significant reduction in the number of HIV particles and a
decrease in the concentration of gp120 and gp24 were
observed, respectively, when treated with Kyberdrug at much
lower concentrations than applied for in the RT-assay.
These concentrations, however, do vary with the pH,
revealing values of 100 ug at pH 6.5 (37 C) versus 20 ug
at pH 7.8 (37 C) .
The anti-HIV activity of the Kyberdrug was
assayed by the MTT method using the MT-4 cell line and the
HIVHTLV-IIIB strain to give the EC50 value, which is the
concentration effective for 50% inhibition of the virus
infection to MT-4 cells by the Kyberdrug. In spite of the
hydrodynamically large size of the Kyberdrug in contrast to
drugs with low molecular weights administered to patients
suffering from HIV infections, all preparations of the
Kyberdrug exhibited anti-HIV activities represented by low
-112-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
EC50 values ranging from 0.4 to 0.6 pg per mL when
administered to the cell cultures in 0.154 M NaCl. pH
changes or different ionic strength did not change the EC50
values significantly. Furthermore, the cytotoxicity of the
Kyberdrug as obtained through the CC50 value were greater
than 800 pg per mL and no changes have been observed in the
CC50 values above 1000 pg per mL which is above the amount.
The inventors assessed also the dependence of the
anticoagulant activity of the Kyberdrug in this
concentration range by the activated partial thromboplastin
time using heparin as a reference, or dextran sulfate as a
standard reference according to the United States
Pharmacopoeia. They determined no anticoagulant activities
at all concentrations of Kyberdrug applied, which is very
different from those reported for sulfated polysaccharides
having also anti-HIV activities (Fig. 5).
The above preferred embodiments and examples are
given to illustrate the scope and spirit of the present
invention. The embodiments and examples described herein
will make apparent to those skilled in the art other
embodiments and examples. These other embodiments and
examples are within the contemplation of the present
invention. Therefore, the present invention should be
limited only by the appended claims.
-113-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
APPENDIX
Protocol 1. Bioassay of IL-2 using CTLL cell-line
Equipment and regents
= CTLL cell culture
= RPMI 1640 medium
RPMI 1640 medium containing 10% FCS
= Centrifuge (.MSE-ben_chtop)
= Trypan blue
= IL-2 standard
= Test samples
= 96-well microtitre plates.
= 37 C, 5% CO2, humidified incubator
= [3H] thymi dine (25 Ci/m Mol, SmCl/5mis)
= Filter mats
= Liquid scintillation counter system
Method
1. Wash CTLL cells (3 days after feeding) three times
with RPMI 164.0 by centrifuging the cells at250 g for 10 min.
2. Determine viability of the cells, e.g., by Trypan
blue dye exclusions and resuspend cells to a final concentration
of 1 x 105 cells/m1 in RPM! 1640 medium containing 10% FCS.
3. Titrate the IL-2 standard in triplicate in 96-well
microtitre plates. Start the titration at 40 IU/ml IL-2 and then
make serial two-fold dilutions down to 0.019 IU/mi IL-2. Prepare
dilutions of the samples in triplicate. Include a negative
control, i.e., culture medium alone. Each well 'should contain a
volume of 50 u1.
4. Add 50 p.l of the cell suspension to each well and
incubate the plates for 18 h at 37 C in a humidified CO2
incubator.
5. Add 0.5 uCi of tritiated thymidine to each well and
return the plates to the incubator for approximately 4h.
6. Harvest the contents of each well on to filter mats
and determine the radioactivity by liquid scintillation counting.
7. Plot a standard curve of c.p.m versus concentration
of IL-2. For auantitation of activity in unknown samples,
compare test results with standard curve.
z Cells should be >80% viable.
-114-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
Protocol 2. Bioassay of IL-ia using EL4/NOB-1 cell lineb
Equipment and reagents
= EL4/NOB-1 cell culture
= RPMI 1640 medium containing 5% FCS
= IL-i Standard
Test samples
= Plus equipment and reagents as Protocol 1
Method
1. Wash ELa/NOB-1 cells (2 to 3 days after feeding)
twice in RPMI 1630 medium by centrifuging the cells at 250 g for
min and determine the viability as in step (2) of Protocol 1.
2. Resuspend the cells to a final concentration of 5 x
105 cells/ml in RPM! 1640 medium containing 5% FCS.
3. Distribute titrations of an IL-1 standard in
triplicate in 96-well microtitration plates. Start the titration
of the standard at 100 pg/ml IL-i (10 !U/ml) and make serial two-
fold dilutions down to 0.09 pg/ml IL-i (0.009,IU/ml). Make
appropriate dilutions of the samples to be measured for IL-i
activity (either two-fold or ten-fold serial dilutions) in
triplicate. The negative control is culture medium. Each well
should contain a volume of 100 jai at this stage.
4. Add 100 p.l of the washed cell suspension to each
well and incubate the plates for approximately 24 h at 37 C in a
humidified CO2 incubator.
5. Remove 50 u1 of the supernatant from each well and
determine the IL-2 present using the CTLL-2 bioassay (see
Protocol 1) . The amount of IL-2 in the supernatants will be
proportional to the amount of IL-1 in the original samples.
Supernatants from the EL4/NOB-1 cells can be removed and stored
frozen until the IL-2 can be conveniently assayed.
a IL-in and have equal' sensitivity in this assay.
The EL4/NOB-1 cell line also responds to murine TNFa.
Since the NOB-1 bioassay uses the CTLL-2 bioassay as a second
stage, IL-2.and mIL-4 could interfere if present in. the- samples
being tested for IL-1 activity. This can be overcome by pre-
incubating the samples with the EL4/NOB-1 cell line for 4-5 h
followed by thorough washing of the cells prior to steps 4 and 5.
-115-
CA 02436107 2003-04-04
WO 02/28424 PCT/IB01/02284
Scheme I
(Production of Kyberdrua)
Collection of the Individual Specimens from Patients
1
Inoculation of Patient's Specimens on Endo Agar
1
Culturing
1
Collection of Lactose Positive Colony Forms Collect Lactose Positive
Culture
1.
TDA and Indole Analysis of Glucuronidase, for negative or positive
material, if negative continue(-) if positive(+) restart culturing or discard
1
Re-Culturing of Selected E.coli strains on Mikrotiter Plates Covered with
Saccharose
1
Cross-check of selected E.coli strains on Saccharose Plates and Blood-Plates
MUG & Indole Reaction
If (-) negative, continue; If (+) positive, restart or discard
1
Elimination of unidentified and unknown strains with VITEK
1
Cultivation on Bouillon in Bioreactor
1
-116-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
Cultivation on Agar, e.g., Diagonal Agar
Incubation by 37' =1.0 C for 12-18 hours
Test of PCR-Reactive Material
if negative proceed
if positive (+), restart or discard
7
LRins of Diagonal Agar with 0.9% NaCl at 20 = 2.0 C, or 0. 25% phenol
Optional Test of PCR-reactive Material, if negative (-),.proceed if positive
(=),
discard or restart > culturing
Inactivation (75'C) in 0.9% NaCl for 120 minutes
degraded
7
Optional Test of PCR-reactive -Material.
If(-), proceed;
If (=), restart Plaque-Test (Table III)
Test of Sterility by Culturing including Identification
7
Packaging, Control of Sterilir: > Test of Sterility & Culturing, if(-),
Sealing of Vials
-117-
CA 02436107 2003-04-04
WO 02/28424 PCT/IBO1/02284
Scheme II
Downstream-Processing of Kyberdrug
LOW HIGH
Bacterial Mass, Cultured and Grown according to Scheme I.
Dry Biomass (500 g)
Extraction with CHC13/Methanol Aqueous Dispersion (20 -
or CH3CN/Methanol 30 C), Continuous Stirring in
the Presence of 0.154 M NaCl
HPLC-Purification, prep., 25 C
Chromatography, e.g. 100 RP-18 G-10 Permeation (25 C)
(dn/dc)T, , Light Scattering Detection at Chromatography, monitoring 230
550 run. and measure optical rotation nm and 550 nm
Pool optically active Fractions
Pool of optically active Fractions
Lyophilization
Lyophilization
a.)Determination of Phosphate,
and/or Glucosamine, Dissolving in CHCl3/MeOH, or
b.) Determination of Particle Size of
Aggregate After Dissolving in 0.154 CH3CN/MeOH (4:1, v/v), 55 C
M NaCl (20 C) and Validation.
DEAE-Cellulose Chromatography
Sterility Control at 25 C, Column (1.5 x 25 cm)
Fluent: Acetate-Propionate
Particle size is multiple of 1,900
Gradient: 0.0-0.75 M NH4 CH3000,
Total 1.1 Lin.CH3CN/MeOH (4:1, v/v)
Fractions pooled after determination of
1. peak at 0.05 M NaCl (large), phosphate content
Kyberdrug-' no phosphate
2. peak at 0.50 M salt (small)
-118-
CA 02436107 2003-04-04
WO 02/28424 PCT/IBO1/02284
TABLE i
Growth and Selection Media, Formulated for
the specific Microorganisms
A.
Peptone j lO.Og
D- (=) -Glucos.e= 40.0 g
Agar-Agar 310. 0 .'Cr
KF2PO4 4. 0 Cr
Na2H?O; 6.0 g
Distilled Water 1.0 L
_oH, or adjusted to 17.0-7.5
B.
Peptone 5.0 a
Yeast Extract 2.5 g
D- (-) -Glucose '.25 c
Maltose, _.25 c
L 0.125
g
Salts Solution 10.0 mL
Reazur_n (0.0025 % ac. sot .) I 1.0 mL
250 IlL
Distilled Wazer
C.
3
Salt Sclution, Ccmccs_ticn of
{_: ~n 10.10 c
_IaHCC I _ . 0 a
~icSC. ) . 2
-119-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
-7a..~SO, = 2 20 0.02-0.05
! c
CCC1.2 = 6 _,0 5.0 kg
HMSO, (5 _0%) 0.3 mL
Distilled Water 100 mL
pH (37 C) 6.8 to 7.8'
D.
Agar-Agar
Soybean Agar total of 100.0 g
White Soybean 100.0 g
Grew Soybean 75.0 g
Distilled Water f 1.0 L
Soak beans overnight. Autoclave 1 hour at 121 C. Filter broth
through cotton. Measure broth and add 1. 5(W/W) Afar.
Sterilize.
E.
Yeast-C- ucose-Citrate Medium
Glucose 10.0 g
Peptone 10.0 g
Yeast Exzracz 5 . 0 g
(r) - S -Adenosy'_methionine = _' ?C 0.125 g
Ammonium C=trace 5.0 g
Sodium Acetate 2.0 g
30r_so. = 4 ..0 0.05 g
''weer 80 I _.0 g
fAd-ust cc ;.H 13.5
-120-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
F. T s a:-,.=- media 1=S F . , but in addi t'_on add 100 V1g
m_tcr_ic_n C, -H 6.5, ..7 C.
}gig
G. The same media as l istead under F. , but -in addition to 1-00
mitomycin C add 0.150 g L-(-)-methionine, but no S-(-)-
adenosy l meth_oni ne = =-,PO, p G. 5 at 37'C.
-121-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
TABLE II
Growth Selection Media Formulated for the Optimized
Culture and Production of Kyberdrug
Peptone, Beef 7.8 g
Peptone, Casein 7.8 g
Yeast Extract. 2.8 g
NaCl 5.6 g
D-(+)-Glucose 1.0 g
Agar-Agar 12.0 g
Distilled Water 1.0 L
or
Peptone, beef 5.0 g
Peptone, casein 5.0 g
Yeast Extract 3.0 g
NaCl 6.0 g
Water soluble Vitamins 600 gg
B61 B1, B12 250, 150 200 gg
L-(-)-Methionine 0.150 g
D-(+)-Glucose 1.0 g
Agar-Agar 12.0 g
Distilled Water 1..0 L
-122-
CA 02436107 2003-04-04
WO 02/28424 PCT/IB01/02284
TABLE III
Selective Criteria for the Production of Kyberdrug
1. Identification of Enterobacteriaceae
E. Coli
Endo Agar R or, S-Forms
Preferable-Diagonal Agar
MUG Reaction negative
Indole Reaction negative
Colicin Determination positive
2. Exclusion Criteria and Requirements for Pathological Strains
and Factors 0
Generation of Hemolysins negative
Formation of Endotoxins negative
Absence of Genes responsible
for Verotoxins:
-heat insensitive no activities
-heat labile forms no activities
Absence of activation factors positive
for cAMP Adenylate-cyclase
Absence of activation factors positive
for cGMP Guanylate-cyclase
Determination of adhesion negative
molecules, e.g., ICAM I-III
Absence of eae gene sequences, positive
characteristic for EHEC or
EPEC
Stability during storage and positive
-123-
CA 02436107 2003-04-04
WO 02/28424 PCT/1B01/02284
effective for shelf-life of
the col+ strain in isotonic
salt solution
'Stability during storage and' positive
effective for self-life of the
col strain in isotonic
solution, but having a
positive indole & MUG"
reaction
No detrimental effects e.g. positive
protease attack on proteins or
degradation of glycolipids and
lipid A on the selected strain
for application -in further
culturing and harvesting
Proven effective at low cell 104-106 cells/ML
numbers
Proven effective at low 1.0 x 10-5 g/mL to 5.0 x 10-6
concentrations g/mL
" MUG=hydroxycoumarin-7-glucoside which is also known as
umbelliforme-7-glucoside.
PCR = polymerase chain reaction
-124-
